GE protein antigen variant as well as preparation method and application thereof

By truncating gE protein antigen variants and RNA vaccine technology, the problem of insufficient safety and effectiveness of existing shingles vaccines has been solved, achieving a more efficient and safer immune response, and reducing the risk of side reactions.

CN118955655AActive Publication Date: 2024-11-15BEIJING WESTAR BIOSCIENCES CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202410730877.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-12-21
Filing Date
2024-06-06
Publication Date
2024-11-15
Estimated Expiration
2044-06-06

AI Technical Summary

Technical Problem

Existing shingles vaccines have problems with insufficient safety and effectiveness, especially live attenuated vaccines may lead to latent infections and side effects, while subunit vaccines are weak in activate cellular immune responses, and the use of adjuvant increases side effects Risk and costly.

Method used

Develop a gE protein antigen variant that generates highly immunogenic antigenic variants by truncating the carboxy terminus of specific amino acid residues and utilizing RNA vaccine technology to improve immune responses, combining specific vectors and adjuvants to improve Safety and effectiveness.

Benefits of technology

A safer and more efficient immune response is achieved, reducing side reaction risks and relatively low costs, providing a potential solution to replace the shortcomings of existing vaccines.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955655A_ABST
    Figure CN118955655A_ABST
Patent Text Reader

Abstract

The invention discloses a gE protein antigen variant as well as a preparation method and application thereof, and provides the gE protein antigen variant which specifically comprises truncation of the carboxyl terminal of any one amino acid residue from the 547th amino acid residue to the 623rd amino acid residue of the gE protein, and the invention also provides a nucleic acid molecule for coding the gE protein antigen variant, and a nucleic acid molecule for coding the gE protein antigen variant, or a nucleic acid molecule for coding the gE protein antigen variant, or a nucleic acid molecule for coding the gE protein antigen variant or a nucleic acid molecule for coding the gE protein antigen variant or a nucleic acid molecule for coding the gE protein antigen variant. The present invention also relates to a carrier comprising the nucleic acid molecule, a cell comprising the carrier, and a pharmaceutical composition comprising the nucleic acid molecule, the carrier, and the cell. The invention also provides a vaccine and a derivative of the gE protein antigen variant. The invention provides application of the gE protein antigen variant in preparation of a product for detecting varicella-zoster virus and application of the gE protein antigen variant in preparation, capture or screening of an antibody for identifying varicella-zoster virus gE protein. The gE protein antigen variant disclosed by the invention is high in application value and wide in market prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology and relates to a gE protein antigen variant, a preparation method and application thereof. Background Art

[0002] Herpes zoster (HZ) is an acute infectious skin disease caused by the varicella-zoster virus (VZV). After infecting the body, the VZV virus can remain dormant in the neurons of the dorsal root ganglia of the spinal cord for a long time. When the body's immune function is reduced, VZV will be reactivated and spread along the nerve fibers to the skin, causing a strong inflammatory response in the infected nerve and skin systems, leading to herpes zoster. HZ usually manifests as a rash that appears on one side of the body and is accompanied by pain and itching, which can last for two to four weeks, and the risk of disease increases with age. A common complication is postherpetic neuralgia, which can last for months to years, seriously affecting the patient's normal work and life.

[0004] Vaccination against HZ is an important means to reduce the incidence of HZ disease. For herpes zoster, the types of HZ vaccines that have been marketed and used worldwide are mainly HZ live attenuated vaccine (zoster vaccine, live attenuated, ZVL) and HZ recombinant protein vaccine (recombinant zoster vaccine, RZV).

[0005] One is a live attenuated vaccine developed by Merck and approved for marketing in 2006, trade name: Zostervax, and a live attenuated vaccine developed by Changchun Biopharma, trade name: HZV-live, approved for marketing in 2023; the other is a subunit adjuvant vaccine developed by GlaxoSmithKline (GSK), trade name: Shingrix, which was first approved for marketing in North America in 2017. However, both vaccines have shortcomings in terms of effectiveness.

[0006] The live attenuated vaccine uses the varicella-zoster virus Oka strain, which is the same strain used in the vaccine to prevent chickenpox, but the potency is more than 10 times higher than that of the varicella vaccine. The disadvantage of this vaccine is that the vaccine may establish a latent infection in the ganglia, which can then be reactivated to cause herpes zoster. In addition, live attenuated viruses are not suitable for all subjects, including patients with insufficient immune function, including those who are immunosuppressed due to leukemia, lymphoma, systemic malignancies, immunodeficiency diseases or immunosuppressive therapy, and this group of people is at high risk of herpes zoster. Merck's Zostavax live attenuated vaccine reduces the incidence of herpes zoster by 69.8% in people with normal immune function aged 50 to 59 years, while the incidence of herpes zoster, PHN incidence and disease burden in people aged ≥60 years after vaccination are reduced by 51.3%, 66.5% and 61.1% respectively; the prevention efficiency of Zostavax gradually decreases with the age of the vaccine recipient, and severe immunosuppression and pregnant women are contraindications to vaccination. Therefore, the need to prepare safer and more effective vaccines is particularly urgent.

[0007] The herpes zoster subunit vaccine developed by GSK, which is made of VZV gE recombinant protein and AS01B adjuvant, reduced the incidence of herpes zoster and PHN by 97.2% and 91.2% respectively in people aged ≥50 with normal immune function, and by 89.8% and 88.8% respectively in people aged ≥70, which is better than the live attenuated vaccine. The disadvantage of Shingrix is ​​that as a subunit vaccine, it is naturally insufficient in activating cellular immune responses and requires the use of adjuvants. Clinical studies have found that the protective effect of herpes zoster is mainly related to the CD4+ / - / - induced by the vaccine. + T cell immune response. However, subunit vaccines are weak in activating cellular immune responses. In order to induce stronger cellular immune responses than live attenuated vaccines, very potent adjuvants, such as AS01B adjuvant, must be added. The addition of adjuvant AS01B increases the toxic and side effects of the Shingrix vaccine. According to reports, in Shingrix clinical studies, more than 10% of subjects experienced grade 3 adverse reactions, including fatigue and pain, headaches, etc. In addition, AS01B's key ingredient, QS21, is a polysaccharide mixture that can only be extracted from the bark of the sapodilla tree grown in temperate regions of South America by reverse HPLC. It cannot be synthesized artificially at present, and has limitations such as limited sources, difficulty in quality control of the preparation process, and the need to add a detoxifying agent due to its hemolytic activity. This has led to Shingrix's high price (US$150-200 per injection, 2 injections for the entire course), and it is still in short supply. Summary of the invention

[0008] In order to solve the technical problems existing in the prior art, the following technical solutions are provided:

[0009] The present invention provides a gE protein antigen variant, which comprises a truncation of the carboxyl terminus of any one amino acid residue selected from amino acid residues 547 to 623 in the gE antigen, wherein the position of the amino acid residue refers to the amino acid sequence SEQ ID NO: 1 (MGTVNKPVVGVLMGFGIITGTLRITNPVRASVLRYDDFHIDEDKLDTNSVYEPYYHSDHAESSWVNRGES).

[0010] In an embodiment of the present invention, the truncation of the carboxyl terminus of the amino acid residue at position X refers to retaining the amino acid residues at positions 1 to X and truncating the consecutive amino acid residues from the amino acid residue at position X+1 to the carboxyl terminus in the direction from the amino terminus (N-terminus) to the carboxyl terminus (C-terminus). In a specific embodiment of the present invention, the "amino acid at position "X" means the amino acid corresponding to the amino acid at position "X" in the gE protein of the VZV oka strain of SEQ ID NO: 1. Note that when a VZV strain other than the oka strain is used, the amino acid positions of the gE protein will be numbered by aligning the sequences of other RSV strains with the gE protein of SEQ ID NO: 1 by inserting gaps where necessary, with reference to the numbering of the gE protein of the oka strain of SEQ ID NO: 1. Sequence alignment can be performed using methods well known in the art, for example, by CLUSTALW, Bioedit or CLC Workbench.

[0011] In certain specific embodiments, the gE protein antigen variant is selected from position 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585 85th, 586th, 587th, 588th, 589th, 590th, 591st, 592nd, 593rd, 594th, 595th, 596th, 597th, 598th, 599th, 600th, 601st, 602nd, 603rd, 604th, 605th, 606th 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, and 623 amino acid residues.

[0012] The term "amino acid residue" specifically includes alanine (Ala or A), cysteine ​​(Cys or C), aspartic acid (Asp or D), glutamic acid (Glu or E), phenylalanine (Phe or F), glycine (Gly or G), histidine (His or H), isoleucine (Ile or I), lysine (Lys or K), leucine (Leu or L), methionine (Met or M), asparagine (Asn or N), proline (Pro or P), glutamine (Gln or Q), arginine (Arg or R), serine (Ser or S), threonine (Thr or T), valine (Val or V), tryptophan (Trp or W) and tyrosine (Tyr or Y) residues. The term "amino acid residue" can also include non-standard, unconventional or non-natural amino acids, which can optionally include amino acids except any of the following amino acids: alanine, cysteine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, valine, tryptophan and tyrosine residues. The term "amino acid residue" can include α-, β-, γ- and δ-amino acids.

[0013] Further, the gE protein antigen variant includes a polypeptide with a carboxyl terminal truncation of an amino acid residue selected from positions 547, 551, 556, 561, 566, 571, 576, 581, 586, 591, 596, 601, 606, 611, 616, and 621.

[0014] Furthermore, the amino acid sequence of the gE protein antigen variant has at least 90%, preferably at least 95%, preferably at least 96%, preferably at least 97%, preferably at least 97%, preferably at least 98%, and preferably at least 99% identity with the amino acid sequence shown in any one of SEQ ID NOs: 2-18.

[0015] Furthermore, the gE protein antigen variant is selected from the following amino acid sequences:

[0016] SEQ ID NO: 2 (carboxyl-terminal truncation of amino acid residue 547 of gE antigen):

[0017] MGTVNKPVVGVLMGFGIITGTLRITNPVRASVLRYDDFHIDEDKLDTNSVYEPYYHSDHAESSWVNRGESSR

[0018] KAYDHNSPYIWPRNDYDGFLENAHEHHGVYNQGRGIDSGERLMQPTQMSAQEDLGDDTGIHVIPTLNGDDR

[0019] HKIVNVDQRQYGDVFKGDLNPKPQGQRLIEVSVEENHPFTLRAPIQRIYGVRYTETWSFLPSLTCTGDAAPAI

[0020] QHICLKHTTCFQDVVVDVDCAENTKEDQLAEISYRFQGKKEADQPWIVVNTSTLFDELELDPPEIEPGVLKVL

[0021] RTEKQYLGVYIWNMRGSDGTSTYATFLVTWKGDEKTRNPTPAVTPQPRGAEFHMWNYHSHVFSVGDTFSLA

[0022] MHLQYKIHEAPFDLLLEWLYVPIDPTCQPMRLYSTCLYHPNAPQCLSHMNSGCTFTSPHLAQRVASTVYQNC

[0023] EHADNYTAYCLGISHMEPSFGLILHDGGTTLKFVDTPESLSGLYVFVVYFNGHVEAVAYTVVSTVDHFVNAIEERGFPPTAGQPPATTKPKEITPVNPGTSPLLRYAAWTGGLAA;

[0024] SEQ ID NO:3 (Truncation at the carboxyl terminus of amino acid residue 551 of the gE antigen):

[0025] MGTVNKPVVGVLMGFGIITGTLRITNPVRASVLRYDDFHIDEDKLDTNSVYEPYYHSDHAESSWVNRGESSR

[0026] KAYDHNSPYIWPRNDYDGFLENAHEHHGVYNQGRGIDSGERLMQPTQMSAQEDLGDDTGIHVIPTLNGDDR

[0027] HKIVNVDQRQYGDVFKGDLNPKPQGQRLIEVSVEENHPFTLRAPIQRIYGVRYTETWSFLPSLTCTGDAAPAI

[0028] QHICLKHTTCFQDVVVDVDCAENTKEDQLAEISYRFQGKKEADQPWIVVNTSTLFDELELDPPEIEPGVLKVL

[0029] RTEKQYLGVYIWNMRGSDGTSTYATFLVTWKGDEKTRNPTPAVTPQPRGAEFHMWNYHSHVFSVGDTFSLA

[0030] MHLQYKIHEAPFDLLLEWLYVPIDPTCQPMRLYSTCLYHPNAPQCLSHMNSGCTFTSPHLAQRVASTVYQNC

[0031] EHADNYTAYCLGISHMEPSFGLILHDGGTTLKFVDTPESLSGLYVFVVYFNGHVEAVAYTVVSTVDHFVNAIEERGFPPTAGQPPATTKPKEITPVNPGTSPLLRYAAWTGGLAAVVLL;

[0032] SEQ ID NO:4 (Truncation at the carboxyl terminus of amino acid residue 556 of the gE antigen):

[0033] MGTVNKPVVGVLMGFGIITGTLRITNPVRASVLRYDDFHIDEDKLDTNSVYEPYYHSDHAESSWVNRGESSR

[0034] KAYDHNSPYIWPRNDYDGFLENAHEHHGVYNQGRGIDSGERLMQPTQMSAQEDLGDDTGIHVIPTLNGDDR

[0035] HKIVNVDQRQYGDVFKGDLNPKPQGQRLIEVSVEENHPFTLRAPIQRIYGVRYTETWSFLPSLTCTGDAAPAI

[0036] QHICLKHTTCFQDVVVDVDCAENTKEDQLAEISYRFQGKKEADQPWIVVNTSTLFDELELDPPEIEPGVLKVL

[0037] RTEKQYLGVYIWNMRGSDGTSTYATFLVTWKGDEKTRNPTPAVTPQPRGAEFHMWNYHSHVFSVGDTFSLA

[0038] MHLQYKIHEAPFDLLLEWLYVPIDPTCQPMRLYSTCLYHPNAPQCLSHMNSGCTFTSPHLAQRVASTVYQNC

[0039] EHADNYTAYCLGISHMEPSFGLILHDGGTTLKFVDTPESLSGLYVFVVYFNGHVEAVAYTVVSTVDHFVNAIEERGFPPTAGQPPATTKPKEITPVNPGTSPLLRYAAWTGGLAAVVLLCLVIF;

[0040] SEQ ID NO:5 (C-terminal truncation of the 561st amino acid residue of the gE antigen):

[0041] MGTVNKPVVGVLMGFGIITGTLRITNPVRASVLRYDDFHIDEDKLDTNSVYEPYYHSDHAESSWVNRGESSR

[0042] KAYDHNSPYIWPRNDYDGFLENAHEHHGVYNQGRGIDSGERLMQPTQMSAQEDLGDDTGIHVIPTLNGDDR

[0043] HKIVNVDQRQYGDVFKGDLNPKPQGQRLIEVSVEENHPFTLRAPIQRIYGVRYTETWSFLPSLTCTGDAAPAI

[0044] QHICLKHTTCFQDVVVDVDCAENTKEDQLAEISYRFQGKKEADQPWIVVNTSTLFDELELDPPEIEPGVLKVL

[0045] RTEKQYLGVYIWNMRGSDGTSTYATFLVTWKGDEKTRNPTPAVTPQPRGAEFHMWNYHSHVFSVGDTFSLA

[0046] MHLQYKIHEAPFDLLLEWLYVPIDPTCQPMRLYSTCLYHPNAPQCLSHMNSGCTFTSPHLAQRVASTVYQNC

[0047] EHADNYTAYCLGISHMEPSFGLILHDGGTTLKFVDTPESLSGLYVFVVYFNGHVEAVAYTVVSTVDHFVNAIEERGFPPTAGQPPATTKPKEITPVNPGTSPLLRYAAWTGGLAAVVLLCLVIFLICTA;

[0048] SEQ ID NO:6 (truncation at the carboxyl terminus of the 566th amino acid residue of the gE antigen):

[0049] MGTVNKPVVGVLMGFGIITGTLRITNPVRASVLRYDDFHIDEDKLDTNSVYEPYYHSDHAESSWVNRGESSR

[0050] KAYDHNSPYIWPRNDYDGFLENAHEHHGVYNQGRGIDSGERLMQPTQMSAQEDLGDDTGIHVIPTLNGDDR

[0051] HKIVNVDQRQYGDVFKGDLNPKPQGQRLIEVSVEENHPFTLRAPIQRIYGVRYTETWSFLPSLTCTGDAAPAI

[0052] QHICLKHTTCFQDVVVDVDCAENTKEDQLAEISYRFQGKKEADQPWIVVNTSTLFDELELDPPEIEPGVLKVL

[0053] RTEKQYLGVYIWNMRGSDGTSTYATFLVTWKGDEKTRNPTPAVTPQPRGAEFHMWNYHSHVFSVGDTFSLA

[0054] MHLQYKIHEAPFDLLLEWLYVPIDPTCQPMRLYSTCLYHPNAPQCLSHMNSGCTFTSPHLAQRVASTVYQNC

[0055] EHADNYTAYCLGISHMEPSFGLILHDGGTTLKFVDTPESLSGLYVFVVYFNGHVEAVAYTVVSTVDHFVNAIEERGFPPTAGQPPATTKPKEITPVNPGTSPLLRYAAWTGGLAAVVLLCLVIFLICTAKRMRV;

[0056] SEQ ID NO:7 (Truncation at the carboxyl terminus of amino acid residue 571 of the gE antigen):

[0057] MGTVNKPVVGVLMGFGIITGTLRITNPVRASVLRYDDFHIDEDKLDTNSVYEPYYHSDHAESSWVNRGESSR

[0058] KAYDHNSPYIWPRNDYDGFLENAHEHHGVYNQGRGIDSGERLMQPTQMSAQEDLGDDTGIHVIPTLNGDDR

[0059] HKIVNVDQRQYGDVFKGDLNPKPQGQRLIEVSVEENHPFTLRAPIQRIYGVRYTETWSFLPSLTCTGDAAPAI

[0060] QHICLKHTTCFQDVVVDVDCAENTKEDQLAEISYRFQGKKEADQPWIVVNTSTLFDELELDPPEIEPGVLKVL

[0061] RTEKQYLGVYIWNMRGSDGTSTYATFLVTWKGDEKTRNPTPAVTPQPRGAEFHMWNYHSHVFSVGDTFSLA

[0062] MHLQYKIHEAPFDLLLEWLYVPIDPTCQPMRLYSTCLYHPNAPQCLSHMNSGCTFTSPHLAQRVASTVYQNC

[0063] EHADNYTAYCLGISHMEPSFGLILHDGGTTLKFVDTPESLSGLYVFVVYFNGHVEAVAYTVVSTVDHFVNAIEERGFPPTAGQPPATTKPKEITPVNPGTSPLLRYAAWTGGLAAVVLLCLVIFLICTAKRMRVKAYRV;

[0064] SEQ ID NO:8 (Truncation at the carboxyl terminus of amino acid residue 576 of the gE antigen)

[0065] MGTVNKPVVGVLMGFGIITGTLRITNPVRASVLRYDDFHIDEDKLDTNSVYEPYYHSDHAESSWVNRGESSR

[0066] KAYDHNSPYIWPRNDYDGFLENAHEHHGVYNQGRGIDSGERLMQPTQMSAQEDLGDDTGIHVIPTLNGDDR

[0067] HKIVNVDQRQYGDVFKGDLNPKPQGQRLIEVSVEENHPFTLRAPIQRIYGVRYTETWSFLPSLTCTGDAAPAI

[0068] QHICLKHTTCFQDVVVDVDCAENTKEDQLAEISYRFQGKKEADQPWIVVNTSTLFDELELDPPEIEPGVLKVL

[0069] RTEKQYLGVYIWNMRGSDGTSTYATFLVTWKGDEKTRNPTPAVTPQPRGAEFHMWNYHSHVFSVGDTFSLA

[0070] MHLQYKIHEAPFDLLLEWLYVPIDPTCQPMRLYSTCLYHPNAPQCLSHMNSGCTFTSPHLAQRVASTVYQNC

[0071] EHADNYTAYCLGISHMEPSFGLILHDGGTTLKFVDTPESLSGLYVFVVYFNGHVEAVAYTVVSTVDHFVNAIEERGFPPTAGQPPATTKPKEITPVNPGTSPLLRYAAWTGGLAAVVLLCLVIFLICTAKRMRVKAYRVDKSPY;

[0072] SEQ ID NO:9 (Truncation at the carboxyl terminus of amino acid residue 581 of the gE antigen):

[0073] MGTVNKPVVGVLMGFGIITGTLRITNPVRASVLRYDDFHIDEDKLDTNSVYEPYYHSDHAESSWVNRGESSR

[0074] KAYDHNSPYIWPRNDYDGFLENAHEHHGVYNQGRGIDSGERLMQPTQMSAQEDLGDDTGIHVIPTLNGDDR

[0075] HKIVNVDQRQYGDVFKGDLNPKPQGQRLIEVSVEENHPFTLRAPIQRIYGVRYTETWSFLPSLTCTGDAAPAI

[0076] QHICLKHTTCFQDVVVDVDCAENTKEDQLAEISYRFQGKKEADQPWIVVNTSTLFDELELDPPEIEPGVLKVL

[0077] RTEKQYLGVYIWNMRGSDGTSTYATFLVTWKGDEKTRNPTPAVTPQPRGAEFHMWNYHSHVFSVGDTFSLA

[0078] MHLQYKIHEAPFDLLLEWLYVPIDPTCQPMRLYSTCLYHPNAPQCLSHMNSGCTFTSPHLAQRVASTVYQNC

[0079] EHADNYTAYCLGISHMEPSFGLILHDGGTTLKFVDTPESLSGLYVFVVYFNGHVEAVAYTVVSTVDHFVNAIE

[0080] ERGFPPTAGQPPATTKPKEITPVNPGTSPLLRYAAWTGGLAAVVLLCLVIFLICTAKRMRVKAYRVDKSPYNQSMY;

[0081] SEQ ID NO:10 (C-terminal truncation of the 586th amino acid residue of the gE antigen):

[0082] MGTVNKPVVGVLMGFGIITGTLRITNPVRASVLRYDDFHIDEDKLDTNSVYEPYYHSDHAESSWVNRGESSR

[0083] KAYDHNSPYIWPRNDYDGFLENAHEHHGVYNQGRGIDSGERLMQPTQMSAQEDLGDDTGIHVIPTLNGDDR

[0084] HKIVNVDQRQYGDVFKGDLNPKPQGQRLIEVSVEENHPFTLRAPIQRIYGVRYTETWSFLPSLTCTGDAAPAI

[0085] QHICLKHTTCFQDVVVDVDCAENTKEDQLAEISYRFQGKKEADQPWIVVNTSTLFDELELDPPEIEPGVLKVL

[0086] RTEKQYLGVYIWNMRGSDGTSTYATFLVTWKGDEKTRNPTPAVTPQPRGAEFHMWNYHSHVFSVGDTFSLA

[0087] MHLQYKIHEAPFDLLLEWLYVPIDPTCQPMRLYSTCLYHPNAPQCLSHMNSGCTFTSPHLAQRVASTVYQNC

[0088] EHADNYTAYCLGISHMEPSFGLILHDGGTTLKFVDTPESLSGLYVFVVYFNGHVEAVAYTVVSTVDHFVNAIE

[0089] ERGFPPTAGQPPATTKPKEITPVNPGTSPLLRYAAWTGGLAAVVLLCLVIFLICTAKRMRVKAYRVDKSPYNQSMYYAGLP;

[0090] SEQ ID NO:11 (Truncation at the carboxyl terminus of amino acid residue 591 of the gE antigen):

[0091] MGTVNKPVVGVLMGFGIITGTLRITNPVRASVLRYDDFHIDEDKLDTNSVYEPYYHSDHAESSWVNRGESSR

[0092] KAYDHNSPYIWPRNDYDGFLENAHEHHGVYNQGRGIDSGERLMQPTQMSAQEDLGDDTGIHVIPTLNGDDR

[0093] HKIVNVDQRQYGDVFKGDLNPKPQGQRLIEVSVEENHPFTLRAPIQRIYGVRYTETWSFLPSLTCTGDAAPAI

[0094] QHICLKHTTCFQDVVVDVDCAENTKEDQLAEISYRFQGKKEADQPWIVVNTSTLFDELELDPPEIEPGVLKVL

[0095] RTEKQYLGVYIWNMRGSDGTSTYATFLVTWKGDEKTRNPTPAVTPQPRGAEFHMWNYHSHVFSVGDTFSLA

[0096] MHLQYKIHEAPFDLLLEWLYVPIDPTCQPMRLYSTCLYHPNAPQCLSHMNSGCTFTSPHLAQRVASTVYQNC

[0097] EHADNYTAYCLGISHMEPSFGLILHDGGTTLKFVDTPESLSGLYVFVVYFNGHVEAVAYTVVSTVDHFVNAIE

[0098] ERGFPPTAGQPPATTKPKEITPVNPGTSPLLRYAAWTGGLAAVVLLCLVIFLICTAKRMRVKAYRVDKSPYNQSMYYAGLPVDDFE;

[0099] SEQ ID NO:12 (truncation at the carboxyl terminus of amino acid residue 596 of the gE antigen):

[0100] MGTVNKPVVGVLMGFGIITGTLRITNPVRASVLRYDDFHIDEDKLDTNSVYEPYYHSDHAESSWVNRGESSR

[0101] KAYDHNSPYIWPRNDYDGFLENAHEHHGVYNQGRGIDSGERLMQPTQMSAQEDLGDDTGIHVIPTLNGDDR

[0102] HKIVNVDQRQYGDVFKGDLNPKPQGQRLIEVSVEENHPFTLRAPIQRIYGVRYTETWSFLPSLTCTGDAAPAI

[0103] QHICLKHTTCFQDVVVDVDCAENTKEDQLAEISYRFQGKKEADQPWIVVNTSTLFDELELDPPEIEPGVLKVL

[0104] RTEKQYLGVYIWNMRGSDGTSTYATFLVTWKGDEKTRNPTPAVTPQPRGAEFHMWNYHSHVFSVGDTFSLA

[0105] MHLQYKIHEAPFDLLLEWLYVPIDPTCQPMRLYSTCLYHPNAPQCLSHMNSGCTFTSPHLAQRVASTVYQNC

[0106] EHADNYTAYCLGISHMEPSFGLILHDGGTTLKFVDTPESLSGLYVFVVYFNGHVEAVAYTVVSTVDHFVNAIE

[0107] ERGFPPTAGQPPATTKPKEITPVNPGTSPLLRYAAWTGGLAAVVLLCLVIFLICTAKRMRVKAYRVDKSPYNQSMYYAGLPVDDFEDSEST;

[0108] SEQ ID NO:13(truncation at the carboxyl terminus of amino acid residue 601 of the gE antigen):

[0109] MGTVNKPVVGVLMGFGIITGTLRITNPVRASVLRYDDFHIDEDKLDTNSVYEPYYHSDHAESSWVNRGESSR

[0110] KAYDHNSPYIWPRNDYDGFLENAHEHHGVYNQGRGIDSGERLMQPTQMSAQEDLGDDTGIHVIPTLNGDDR

[0111] HKIVNVDQRQYGDVFKGDLNPKPQGQRLIEVSVEENHPFTLRAPIQRIYGVRYTETWSFLPSLTCTGDAAPAI

[0112] QHICLKHTTCFQDVVVDVDCAENTKEDQLAEISYRFQGKKEADQPWIVVNTSTLFDELELDPPEIEPGVLKVL

[0113] RTEKQYLGVYIWNMRGSDGTSTYATFLVTWKGDEKTRNPTPAVTPQPRGAEFHMWNYHSHVFSVGDTFSLA

[0114] MHLQYKIHEAPFDLLLEWLYVPIDPTCQPMRLYSTCLYHPNAPQCLSHMNSGCTFTSPHLAQRVASTVYQNC

[0115] EHADNYTAYCLGISHMEPSFGLILHDGGTTLKFVDTPESLSGLYVFVVYFNGHVEAVAYTVVSTVDHFVNAIE

[0116] ERGFPPTAGQPPATTKPKEITPVNPGTSPLLRYAAWTGGLAAVVLLCLVIFLICTAKRMRVKAYRVDKSPYNQSMYYAGLPVDDFEDSESTDTEEE);

[0117] SEQ ID NO:14 (truncation at the carboxyl terminus of amino acid residue 606 of the gE antigen):

[0118] MGTVNKPVVGVLMGFGIITGTLRITNPVRASVLRYDDFHIDEDKLDTNSVYEPYYHSDHAESSWVNRGESSR

[0119] KAYDHNSPYIWPRNDYDGFLENAHEHHGVYNQGRGIDSGERLMQPTQMSAQEDLGDDTGIHVIPTLNGDDR

[0120] HKIVNVDQRQYGDVFKGDLNPKPQGQRLIEVSVEENHPFTLRAPIQRIYGVRYTETWSFLPSLTCTGDAAPAI

[0121] QHICLKHTTCFQDVVVDVDCAENTKEDQLAEISYRFQGKKEADQPWIVVNTSTLFDELELDPPEIEPGVLKVL

[0122] RTEKQYLGVYIWNMRGSDGTSTYATFLVTWKGDEKTRNPTPAVTPQPRGAEFHMWNYHSHVFSVGDTFSLA

[0123] MHLQYKIHEAPFDLLLEWLYVPIDPTCQPMRLYSTCLYHPNAPQCLSHMNSGCTFTSPHLAQRVASTVYQNC

[0124] EHADNYTAYCLGISHMEPSFGLILHDGGTTLKFVDTPESLSGLYVFVVYFNGHVEAVAYTVVSTVDHFVNAIE

[0125] ERGFPPTAGQPPATTKPKEITPVNPGTSPLLRYAAWTGGLAAVVLLCLVIFLICTAKRMRVKAYRVDKSPYNQSMYYAGLPVDDFEDSESTDTEEEFGNAI;

[0126] SEQ ID NO: 15 (carboxyl-terminal truncation of amino acid residue 611 of gE antigen):

[0127] MGTVNKPVVGVLMGFGIITGTLRITNPVRASVLRYDDFHIDEDKLDTNSVYEPYYHSDHAESSWVNRGESSR

[0128] KAYDHNSPYIWPRNDYDGFLENAHEHHGVYNQGRGIDSGERLMQPTQMSAQEDLGDDTGIHVIPTLNGDDR

[0129] HKIVNVDQRQYGDVFKGDLNPKPQGQRLIEVSVEENHPFTLRAPIQRIYGVRYTETWSFLPSLTCTGDAAPAI

[0130] QHICLKHTTCFQDVVVDVDCAENTKEDQLAEISYRFQGKKEADQPWIVVNTSTLFDELELDPPEIEPGVLKVL

[0131] RTEKQYLGVYIWNMRGSDGTSTYATFLVTWKGDEKTRNPTPAVTPQPRGAEFHMWNYHSHVFSVGDTFSLA

[0132] MHLQYKIHEAPFDLLLEWLYVPIDPTCQPMRLYSTCLYHPNAPQCLSHMNSGCTFTSPHLAQRVASTVYQNC

[0133] EHADNYTAYCLGISHMEPSFGLILHDGGTTLKFVDTPESLSGLYVFVVYFNGHVEAVAYTVVSTVDHFVNAIE

[0134] ERGFPPTAGQPPATTKPKEITPVNPGTSPLLRYAAWTGGLAAVVLLCLVIFLICTAKRMRVKAYRVDKSPYNQSMYYAGLPVDDFEDSESTDTEEEFGNAIGGSHG;

[0135] SEQ ID NO: 16 (carboxyl-terminal truncation of amino acid residue 616 of gE antigen):

[0136] MGTVNKPVVGVLMGFGIITGTLRITNPVRASVLRYDDFHIDEDKLDTNSVYEPYYHSDHAESSWVNRGESSR

[0137] KAYDHNSPYIWPRNDYDGFLENAHEHHGVYNQGRGIDSGERLMQPTQMSAQEDLGDDTGIHVIPTLNGDDR

[0138] HKIVNVDQRQYGDVFKGDLNPKPQGQRLIEVSVEENHPFTLRAPIQRIYGVRYTETWSFLPSLTCTGDAAPAI

[0139] QHICLKHTTCFQDVVVDVDCAENTKEDQLAEISYRFQGKKEADQPWIVVNTSTLFDELELDPPEIEPGVLKVL

[0140] RTEKQYLGVYIWNMRGSDGTSTYATFLVTWKGDEKTRNPTPAVTPQPRGAEFHMWNYHSHVFSVGDTFSLA

[0141] MHLQYKIHEAPFDLLLEWLYVPIDPTCQPMRLYSTCLYHPNAPQCLSHMNSGCTFTSPHLAQRVASTVYQNC

[0142] EHADNYTAYCLGISHMEPSFGLILHDGGTTLKFVDTPESLSGLYVFVVYFNGHVEAVAYTVVSTVDHFVNAIE

[0143] ERGFPPTAGQPPATTKPKEITPVNPGTSPLLRYAAWTGGLAAVVLLCLVIFLICTAKRMRVKAYRVDKSPYNQSMYYAGLPVDDFEDSESTDTEEEFGNAIGGSHGGSSYT;

[0144] SEQ ID NO:17(truncation at the carboxyl terminus of amino acid residue 621 of the gE antigen):

[0145] MGTVNKPVVGVLMGFGIITGTLRITNPVRASVLRYDDFHIDEDKLDTNSVYEPYYHSDHAESSWVNRGESSR

[0146] KAYDHNSPYIWPRNDYDGFLENAHEHHGVYNQGRGIDSGERLMQPTQMSAQEDLGDDTGIHVIPTLNGDDR

[0147] HKIVNVDQRQYGDVFKGDLNPKPQGQRLIEVSVEENHPFTLRAPIQRIYGVRYTETWSFLPSLTCTGDAAPAI

[0148] QHICLKHTTCFQDVVVDVDCAENTKEDQLAEISYRFQGKKEADQPWIVVNTSTLFDELELDPPEIEPGVLKVL

[0149] RTEKQYLGVYIWNMRGSDGTSTYATFLVTWKGDEKTRNPTPAVTPQPRGAEFHMWNYHSHVFSVGDTFSLA

[0150] MHLQYKIHEAPFDLLLEWLYVPIDPTCQPMRLYSTCLYHPNAPQCLSHMNSGCTFTSPHLAQRVASTVYQNC

[0151] EHADNYTAYCLGISHMEPSFGLILHDGGTTLKFVDTPESLSGLYVFVVYFNGHVEAVAYTVVSTVDHFVNAIE

[0152] ERGFPPTAGQPPATTKPKEITPVNPGTSPLLRYAAWTGGLAAVVLLCLVIFLICTAKRMRVKAYRVDKSPYNQSMYYAGLPVDDFEDSESTDTEEEFGNAIGGSHGGSSYTVYIDK;

[0153] SEQ ID NO:18 (C-terminal truncation of the 623rd amino acid residue of the gE antigen)

[0154] MGTVNKPVVGVLMGFGIITGTLRITNPVRASVLRYDDFHIDEDKLDTNSVYEPYYHSDHAESSWVNRGESSR

[0155] KAYDHNSPYIWPRNDYDGFLENAHEHHGVYNQGRGIDSGERLMQPTQMSAQEDLGDDTGIHVIPTLNGDDR

[0156] HKIVNVDQRQYGDVFKGDLNPKPQGQRLIEVSVEENHPFTLRAPIQRIYGVRYTETWSFLPSLTCTGDAAPAI

[0157] QHICLKHTTCFQDVVVDVDCAENTKEDQLAEISYRFQGKKEADQPWIVVNTSTLFDELELDPPEIEPGVLKVL

[0158] RTEKQYLGVYIWNMRGSDGTSTYATFLVTWKGDEKTRNPTPAVTPQPRGAEFHMWNYHSHVFSVGDTFSLA

[0159] MHLQYKIHEAPFDLLLEWLYVPIDPTCQPMRLYSTCLYHPNAPQCLSHMNSGCTFTSPHLAQRVASTVYQNC

[0160] EHADNYTAYCLGISHMEPSFGLILHDGGTTLKFVDTPESLSGLYVFVVYFNGHVEAVAYTVVSTVDHFVNAIE

[0161] ERGFPPTAGQPPATTKPKEITPVNPGTSPLLRYAAWTGGLAAVVLLCLVIFLICTAKRMRVKAYRVDKSPYNQSMYYAGLPVDDFEDSESTDTEEEFGNAIGGSHGGSSYTVYIDKTR;

[0162] Furthermore, the gE protein antigen variant is selected from the truncation of the carboxyl terminus of the 571st amino acid residue, and the amino acid sequence is shown in SEQ ID NO:7.

[0163] Furthermore, the gE protein antigen variant is selected from the truncation of the carboxyl terminus of the 591st amino acid residue, and the amino acid sequence is shown in SEQ ID NO:11.

[0164] As used herein, the term "antigenic variant" refers to a polypeptide sequence that is different from a specifically recognized sequence, in which one or more amino acid residues are deleted, substituted or added. Variants may be naturally occurring allele antigenic variants or non-naturally occurring antigenic variants. Variants may be from the same species or from other species and may include homologs, paralogs and orthologs. In certain embodiments, the antigenic variants of the polypeptides useful in the present invention have the same or similar biological activities as those of the parent polypeptide, including hormone functions or antigen binding properties. The term "antigenic variant" for (poly)peptides includes all forms of polypeptides defined herein. The term "antigenic variant" includes naturally occurring polypeptides, as well as polypeptides produced by recombinant and synthetic methods.

[0165] The present invention provides a nucleic acid molecule, which comprises a nucleotide sequence encoding the aforementioned gE protein antigen variant.

[0166] The terms "nucleic acid molecule", "coding sequence", "polynucleotide", "nucleotide sequence", "nucleic acid sequence" and "nucleic acid" are used interchangeably and include DNA, RNA or hybrids thereof, which can be double-stranded or single-stranded.

[0167] The present invention provides a vector, which comprises the nucleic acid molecule described above.

[0168] Furthermore, the vector includes a plasmid vector, a lentiviral vector, an adenoviral vector, an adeno-associated viral vector, a piggyBac vector or a Sleeping Beauty transposition vector.

[0169] The term "vector" is used to refer to a carrier nucleic acid molecule into which a nucleic acid sequence can be inserted for introduction into a cell where it can be replicated. The nucleic acid sequence can be "exogenous," meaning that it is foreign to the cell into which the vector is introduced, or that the sequence is homologous to a sequence in the cell. Vectors include plasmids, cosmids, viruses (bacteriophages, animal viruses, and plant viruses), and artificial chromosomes (e.g., YACs).

[0170] The present invention provides a cell, which comprises the aforementioned gE protein antigen variant, the aforementioned nucleic acid molecule, and the aforementioned vector.

[0171] Furthermore, the cell includes a prokaryotic cell or a eukaryotic cell.

[0172] Furthermore, the prokaryotic cells include bacteria and actinomycetes.

[0173] Furthermore, the eukaryotic cells include mammalian cells, insect cells, and yeast cells.

[0174] In certain specific embodiments, the prokaryotic cells include bacteria, such as Escherichia coli, Bacillus subtilis, Salmonella, Pseudomonas, Streptomyces, Staphylococcus. In certain specific embodiments, the mammalian cells include fibroblasts, lymphocytes, epithelial cells, myeloblasts.

[0175] Furthermore, the eukaryotic cells include 293T cells.

[0176] The term "cell" refers to a prokaryotic or eukaryotic cell and its progeny, i.e., any and all descendants. And it includes any transformable organism capable of replicating a vector and / or expressing a heterologous gene encoded by a vector. Cells can and have been used as recipients of vectors. Cells can be "transfected" or "transformed," which refers to the process of transferring or introducing exogenous nucleic acid into a cell, and the transformed cells include primary cells and their progeny.

[0177] The present invention provides a pharmaceutical composition, which comprises the aforementioned gE protein antigen variant, the aforementioned nucleic acid molecule, the aforementioned vector, or the aforementioned cell.

[0178] The present invention provides a vaccine, which comprises an active ingredient, wherein the active ingredient comprises an RNA polynucleotide having an open reading frame encoding at least one of the aforementioned gE protein antigen variants, and / or the aforementioned gE protein antigen variants.

[0179] Furthermore, the vaccine includes RNA vaccine, protein vaccine or viral vector vaccine.

[0180] In a preferred embodiment, the vaccine is an RNA vaccine comprising an RNA polynucleotide having an open reading frame encoding at least the aforementioned gE protein antigen variant.

[0181] Further, the open reading frame of the RNA polynucleotide is codon optimized. Codon optimization methods are known in the art and can be used as provided herein. In some embodiments, codon optimization can be used to match the codon frequency in the target and host organism to ensure proper folding; GC content is biased to increase mRNA stability or reduce secondary structure; tandem repeat codons or base runs that can damage gene structure or expression are minimized; custom transcription and translation control regions; insert or remove protein transport sequences; remove / add post-translational modification sites (e.g., glycosylation sites) in the encoded protein; add, remove or replace protein domains; insert or delete restriction sites; modify ribosome binding sites and mRNA degradation sites; adjust the translation rate so that the various domains of the protein can be properly folded; or reduce or eliminate problematic secondary structures in polynucleotides.

[0182] In some embodiments, codon-optimized RNA can be RNA in which G / C levels are enhanced. The G / C content of a nucleic acid molecule (e.g., mRNA) can affect the stability of RNA. RNA with increased amounts of guanine (G) and / or cytosine (C) residues can be more stable in function than RNA containing a large amount of adenine (A) and thymine (T) or uracil (U) nucleotides. For example, WO02 / 098443 discloses a pharmaceutical composition containing mRNA stabilized by sequence modification in the translation region. Due to genetic code degradation, modification works by replacing existing codons with those codons that promote greater RNA stability without changing the resulting amino acids. The method is confined to the coding region of RNA.

[0183] Furthermore, the RNA polynucleotide comprises at least one chemical modification.

[0184] Further, the chemical modification is selected from any group consisting of pseudouridine, N1-methylpseudouridine, N1-ethylpseudouridine, 2-thiouridine, 4′-thiouridine, 5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine and 2′-O-methyluridine.

[0185] Furthermore, at least 50% of the uracil in the RNA polynucleotide is chemically modified.

[0186] Furthermore, at least 60% of the uracil in the RNA polynucleotide is chemically modified.

[0187] Furthermore, at least 70% of the uracil in the RNA polynucleotide is chemically modified.

[0188] Furthermore, at least 80% of the uracil in the RNA polynucleotide is chemically modified.

[0189] Furthermore, at least 90% of the uracil in the RNA polynucleotide is chemically modified.

[0190] Furthermore, at least 100% of the uracil in the RNA polynucleotide is chemically modified.

[0191] Furthermore, the chemical modification is located at the 5th position of uracil.

[0192] Furthermore, the RNA polynucleotide further comprises a 3'-UTR and / or at least one 5'-UTR.

[0193] Furthermore, the RNA polynucleotide further comprises a 3'-UTR and at least one 5'-UTR.

[0194] Further, each of the at least one 3'-UTR and the at least one 5'-UTR are heterologous to each other.

[0195] Further, the at least one 3'UTR is derived from a gene selected from the group consisting of: housekeeping genes, genes encoding membrane proteins, genes involved in cellular metabolism, genes involved in transcription, translation and replication processes, genes involved in protein modification and genes involved in cell division.

[0196] Further, the at least one 5'-UTR is derived from a gene selected from the group consisting of: housekeeping genes, genes encoding membrane proteins, genes involved in cell metabolism, genes involved in transcription, translation and replication processes, genes involved in protein modification and genes involved in cell division.

[0197] Furthermore, the RNA polynucleotide is capped.

[0198] Furthermore, the capping includes cap0, cap1, and cap2.

[0199] Furthermore, the capping is performed by enzymatic capping or co-transcriptional capping.

[0200] Furthermore, the enzymatic capping comprises capping with a capping enzyme, GTP and S-adenosylmethionine (SAM).

[0201] Furthermore, the co-transcriptional capping includes adding a cap structure analog.

[0202] Furthermore, the cap structure analogs include 7mG(5')ppp(5')N1mpNp or 7mG(5')ppp(5')N1mpNp.

[0203] Furthermore, the RNA polynucleotide is tailed.

[0204] Furthermore, the tailing includes tailing by cleavage and polyadenylation specific factors, cleavage stimulating factors, cleavage factor I and cleavage factor II, poly (A) polymerase, poly (A) binding protein, and paired proteins.

[0205] Furthermore, the tailing includes a poly(A) tail.

[0206] Furthermore, the RNA polynucleotide is capped and tailed.

[0207] Furthermore, the RNA polynucleotide has a 5' terminal cap, an open reading frame encoding at least one of the aforementioned gE protein antigen variants, and a 3' polyadenylation tail.

[0208] Furthermore, the 5′ end cap comprises 7mG(5′)ppp(5′)N1mpNp or comprises 7mG(5′)ppp(5′)N1mpNp.

[0209] Further, the poly(A) tail has a length of about 20 to about 300 adenine nucleotides, preferably about 40 to about 200 adenine nucleotides, more preferably about 50 to about 100 adenine nucleotides, and even more preferably about 60 to about 70 adenine nucleotides.

[0210] Embodiments of the present invention provide RNA (e.g., mRNA) vaccines comprising at least one polynucleotide encoding at least one VZV antigenic polypeptide. The VZV RNA vaccines provided herein can be used to elicit a balanced immune response, including cellular and humoral immunity, without the various risks associated with DNA vaccines and live attenuated vaccines. Various RNA (e.g., mRNA) vaccines disclosed herein produce immune responses in BALB / C mice, and the results are discussed in detail in the Examples section. In particular, RNA (e.g., mRNA) polynucleotide vaccines having open reading frames encoding one or more of the various VZV antigens produce significant immune responses relative to traditional VZV vaccines (e.g., attenuated VZV viruses).

[0211] Furthermore, the RNA vaccine is formulated and delivered on a carrier.

[0212] Furthermore, the carrier includes dendritic cells, cationic nanoemulsion (CNE), cationic polypeptides and polymers, liposome polymers (lipopolyplex, LPR), liposome complexes (lipopolyplex, LPR), and lipid nanoparticles (lipid nanoparticles, LNP).

[0213] Furthermore, the carrier is selected from lipid nanoparticles (LNP).

[0214] Furthermore, the LNP comprises cationic lipids, PEG-modified lipids, sterols and non-cationic lipids.

[0215] Further, the cationic lipid is selected from the group consisting of: 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA) and 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioic acid di((Z)-non-2-en-1-yl) ester (L319).

[0216] In certain specific embodiments, the lipid nanoparticle (LNP) formulation significantly enhances the effectiveness of mRNA vaccines, including chemically modified and unmodified mRNA vaccines. The efficacy of mRNA vaccines formulated in LNP was tested in vivo using several different antigens. The results presented herein show that the mRNA vaccines formulated in LNP are superior to the unexpectedly superior efficacy of other vaccines. In some embodiments, the LNP can be a hydrophilic polymer particle, and in some embodiments, the LNP can be a hydrophobic polymer particle. In some embodiments, the LNP can be a biodegradable cationic lipid of a lipid nanoparticle (reLNP) that is rapidly eliminated, which is used to replace cationic lipids to improve LNP formulations.

[0217] In some embodiments, lipid nanoparticles can be engineered to change the surface properties of particles so that lipid nanoparticles can penetrate mucosal barriers. Lipid nanoparticles that penetrate mucus by engineering can include polymeric materials (e.g., polymeric cores) and / or polymer-vitamin conjugates and / or triblock copolymers. Polymeric materials can include, but are not limited to, polyamines, polyethers, polyamides, polyesters, polyurethanes, polyureas, polycarbonates, poly(styrenes), polyimides, polysulfones, polyurethanes, polyacetylene, polyethylene, polyethylene imine, polyisocyanates, polyacrylates, polymethacrylates, polyacrylonitrile, and polyarylates. Polymeric materials can be biodegradable and / or biocompatible.

[0218] In embodiments of the present invention, the terms "chemical modification" and "chemically modified" refer to modifications to at least one of the positions, patterns, percentages or populations of adenosine (A), guanosine (G), uridine (U), thymidine (T) or cytosine (C) ribonucleosides or deoxyribonucleosides. Typically, the terms do not refer to ribonucleotide modifications to the end cap portion of a naturally occurring 5'-terminal mRNA.

[0219] Modifications of polynucleotides include, but are not limited to, those described herein and include, but are not limited to, those modifications comprising chemical modifications. Polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) may comprise naturally occurring, non-naturally occurring modifications, or polynucleotides may comprise a combination of naturally occurring and non-naturally occurring modifications. Polynucleotides may include, for example, any applicable modification to sugars, nucleobases, or internucleoside linkages (e.g., to linked phosphates, to phosphodiester bonds, or to phosphodiester backbones).

[0220] Modified nucleotide base pairing not only encompasses standard adenosine-thymine, adenosine-uracil or guanosine-cytosine base pairs, but also encompasses base pairs formed between nucleotides and / or modified nucleotides, including non-standard or modified bases, wherein the arrangement of hydrogen bond donors and hydrogen bond acceptors allows hydrogen bonding between non-standard bases and standard bases or between two complementary non-standard base structures, such as in those polynucleotides with at least one chemical modification. An example of the non-standard base pairing is the base pairing between the modified nucleotide inosine and adenine, cytosine or uracil. Any combination of bases / sugars or linkers can be incorporated into the polynucleotides of the present invention.

[0221] In some embodiments of the present invention, the RNA vaccine comprises at least one ribonucleic acid (RNA) polynucleotide having an open reading frame encoding at least one VZV antigenic polypeptide or an immunogenic fragment thereof, wherein at least 50% (e.g., 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, 100%) of the uracils in the open reading frame are chemically modified, optionally wherein the vaccine is formulated in a lipid nanoparticle. In some embodiments, 100% of the uracils in the open reading frame are chemically modified. In some embodiments, the chemical modification is at position 5 of the uracil.

[0222] Modifications (including but not limited to chemical modifications) of polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) suitable for use in the compositions, vaccines, methods and synthetic methods of the present invention include but are not limited to the following or combinations of the following: 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine; 2-methylthio-N6-methyladenosine; 2-methylthio-N6-threonylcarbamoyladenosine; N6-glycinylcarbamoyladenosine; N6-isopentenyladenosine; N6-methyladenosine; N6-threonylcarbamoyladenosine; 1,2′-O-dimethyladenosine; 1-methyladenosine; 2′-O-methyladenosine; 2′-O-ribosyladenosine (phosphate); 2-methyladenosine; 2-methylthio-N6 Isopentenyl adenosine; 2-methylthio-N6-hydroxynorvalylcarbamoyl adenosine; 2′-O-methyladenosine; 2′-O-ribosyl adenosine (phosphate); isopentenyl adenosine; N6-(cis-hydroxyisopentenyl) adenosine; N6,2′-O-dimethyladenosine; N6,2′-O-dimethyladenosine; N6,N6,2′-O-trimethyladenosine; N6,N6-dimethyladenosine; N6-acetyladenosine; N6-hydroxynorvalylcarbamoyl adenosine; N6-methyl-N6-threonylcarbamoyl adenosine; 2-methyladenosine; 2-methylthio-N6-isopentenyl adenosine; 7-deaza-adenosine; N1-methyl-adenosine; N6,N6 (dimethyl) adenine; N6-cis-hydroxy-isopentyl alkenyl-adenosine; α-thio-adenosine; 2(amino)adenine; 2(aminopropyl)adenine; 2(methylthio)N6(isopentenyl)adenine; 2-(alkyl)adenine; 2-(aminoalkyl)adenine; 2-(aminopropyl)adenine; 2-(halo)adenine; 2-(halo)adenine; 2-(propyl)adenine; 2′-amino-2′-deoxy-ATP; 2′-azido-2′-deoxy-ATP; 2′-deoxy-2′-a-aminoadenosine TP; 2′-deoxy-2′-a-azidoadenosine TP; 6(alkyl)adenine; 6(methyl)adenine; 6-(alkyl)adenine; 6-(methyl)adenine; 7(deaza)adenine; 8(alkenyl)adenine; 8(alkyne 8-(amino)adenine; 8-(sulfanyl)adenine; 8-(alkenyl)adenine; 8-(alkyl)adenine; 8-(alkynyl)adenine; 8-(amino)adenine; 8-(halo)adenine; 8-(hydroxy)adenine; 8-(sulfanyl)adenine; 8-(thiol)adenine; 8-azido-adenosine; azaadenine; deazaadenine; N6(methyl)adenine; N6-(isopentyl)adenine; 7-deaza-8-aza-adenosine; 7-methyladenine; 1-deazaadenosine TP; 2′-fluoro-N6-Bz-deoxyadenosine TP; 2′-OMe-2-amino-ATP; 2′O-methyl-N6-Bz-deoxyadenosine TP; 2′-a-ethynyladenosine TP;2-aminoadenine; 2-aminoadenosine TP; 2-amino-ATP; 2′-a-trifluoromethyladenosine TP; 2-azidoadenosine TP; 2′-b-ethynyladenosine TP; 2-bromoadenosine TP; 2′-b-trifluoromethyladenosine TP; 2-chloroadenosine TP; 2′-deoxy-2′,2′difluoroadenosine TP; 2′-deoxy-2′-a-thioadenosine TP; 2′-deoxy-2′-a-thiomethoxyadenosine TP; 2′-deoxy-2′-b-aminoadenosine TP; 2′-deoxy-2′-b-azidoadenosine TP; 2′-deoxy-2′-b-bromoadenosine TP; 2′-deoxy-2′-b-chloroadenosine TP; 2′-deoxy-2′-b-fluoroadenosine TP; 2′- Deoxy-2′-b-iodoadenosine TP; 2′-deoxy-2′-b-thioadenosine TP; 2′-deoxy-2′-b-thiomethoxyadenosine TP; 2-fluoroadenosine TP; 2-iodoadenosine TP; 2-thioadenosine TP; 2-methoxy-adenine; 2-methylthio-adenine; 2-trifluoromethyladenosine TP; 3-deaza-3-bromoadenosine TP; 3-deaza-3-chloroadenosine TP; 3-deaza-3-fluoroadenosine TP; 3-deaza-3-iodoadenosine TP; 3-deazaadenosine TP; 4′-azidoadenosine TP; 4′-carbocyclic adenosine TP; 4′-ethynyladenosine TP; 5′-homo-adenosine TP; 8-aza-ATP; 8-bromoadenosine TP; 8-trifluoromethyladenosine TP; 9-deazaadenosine TP; 2-aminopurine; 7-deaza-2,6-diaminopurine; 7-deaza-8-aza-2,6-diaminopurine; 7-deaza-8-aza-2-aminopurine; 2,6-diaminopurine; 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine; 2-thiocytidine; 3-methylcytidine; 5-formylcytidine; 5-hydroxymethylcytidine; 5-methylcytidine; N4-acetylcytidine; 2′-O-methylcytidine; 2′-O-methylcytidine; 5,2′-O-dimethylcytidine; 5-formyl-2′-O-methylcytidine; Lysidine; N4,2′-O-dimethylcytidine; N4-acetyl-2′-O-methylcytidine; N4-methylcytidine; N4,N4-dimethyl-2′-OMe-cytidine TP; 4-methylcytidine; 5-aza-cytidine; pseudo-iso-cytidine; pyrrolo-cytidine; α-thio-cytidine; 2-(thio)cytidine; 2′-amino-2′-deoxy-CTP; 2′-azido-2′-deoxy-CTP; 2′-deoxy-2′-a-aminocytidine TP; 2′-deoxy-2′-a-azidocytidine TP; 3(deaza)5(aza)cytidine; 3(methyl)cytosine; 3-(alkyl)cytosine;3-(deaza)5(aza)cytosine; 3-(methyl)cytidine; 4,2′-O-dimethylcytidine; 5(halo)cytosine; 5(methyl)cytosine; 5(propynyl)cytosine; 5(trifluoromethyl)cytosine; 5-(alkyl)cytosine; 5-(alkynyl)cytosine; 5-(halo)cytosine; 5-(propynyl)cytosine; 5-(trifluoromethyl)cytosine; 5-bromo-cytosine; 5-iodo-cytosine; 5-propynylcytosine; 6-(azo)cytosine; 6-aza-cytosine; azacytosine; deazacytosine; N4(acetyl)cytosine; 1-methyl-1-deaza-pseudoisocytidine; 1-methyl-pseudoisocytidine; 2- Methoxy-5-methyl-cytidine; 2-methoxy-cytidine; 2-thio-5-methyl-cytidine; 4-methoxy-1-methyl-pseudoisocytidine; 4-methoxy-pseudoisocytidine; 4-thio-1-methyl-1-deaza-pseudoisocytidine; 4-thio-1-methyl-pseudoisocytidine; 4-thio-pseudoisocytidine; 5-aza-zebularine; 5-methyl-zebularine; pyrrolo-pseudoisocytidine; zebularine; (E)-5-(2-bromo-vinyl)cytidine TP; 2,2′-anhydro-cytidine TP hydrochloride; 2′fluoro-N4-Bz-cytidine TP; 2′fluoro-N4 -acetyl-cytidine TP; 2′-O-methyl-N4-acetyl-cytidine TP; 2′O-methyl-N4-Bz-cytidine TP; 2′-a-ethynylcytidine TP; 2′-a-trifluoromethylcytidine TP; 2′-b-ethynylcytidine TP; 2′-b-trifluoromethylcytidine TP; 2′-deoxy-2′,2′-difluorocytidine TP; 2′-deoxy-2′-a-thiolcytidine TP; 2′-deoxy-2′-a-thiomethoxycytidine TP; 2′-deoxy-2′-b-aminocytidine TP; 2′-deoxy-2′-b-azidocytidine TP; 2′-deoxy-2 '-b-bromocytidine TP; 2'-deoxy-2'-b-chlorocytidine TP; 2'-deoxy-2'-b-fluorocytidine TP; 2'-deoxy-2'-b-iodocytidine TP; 2'-deoxy-2'-b-thiolcytidine TP; 2'-deoxy-2'-b-thiomethoxycytidine TP; 2'-O-methyl-5-(1-propynyl)cytidine TP; 3'-ethynylcytidine TP; 4'-azidocytidine TP; 4'-carbocyclic cytidine TP; 4'-ethynylcytidine TP; 5-(1-propynyl)arabino-cytidine TP; 5-(2-chloro-phenyl)-2-thiocytidine TP;5-(4-amino-phenyl)-2-thiocytidine TP; 5-aminoallyl-CTP; 5-cyanocytidine TP; 5-ethynylaza-cytidine TP; 5-ethynylcytidine TP; 5′-homo-cytidine TP; 5-methoxycytidine TP; 5-trifluoromethyl-cytidine TP; N4-amino-cytidine TP; N4-benzoyl-cytidine TP; pseudoisocytidine; 7-methylguanosine; N2,2′-O-dimethylguanosine; N2-methylguanosine; Wyosine; 1,2′-O-dimethylguanosine; 1-methylguanosine; 2′-O-methylguanosine; 2′-O-ribosylguanosine (phosphate); 2′-O-methylguanosine guanosine; 2′-O-ribosylguanosine (phosphate); 7-aminomethyl-7-deazaguanosine; 7-cyano-7-deazaguanosine; archaeosine; methyl wyosine; N2,7-dimethylguanosine; N2,N2,2′-O-trimethylguanosine; N2,N2,7-trimethylguanosine; N2,N2-dimethylguanosine; N2,7,2′-O-trimethylguanosine; 6-thioguanosine; 7-deazaguanosine; 8-oxoguanosine; N1-methylguanosine; α-thioguanosine; 2(propyl)guanine; 2-(alkyl)guanine; 2′-amino-2′-deoxy-GTP; 2′-azido-2′-deoxy-GTP; 2′-deoxy-2′-a- aminoguanosine TP; 2′-deoxy-2′-a-azidoguanosine TP; 6(methyl)guanine; 6-(alkyl)guanine; 6-(methyl)guanine; 6-methyl-guanosine; 7(alkyl)guanine; 7(deaza)guanine; 7(methyl)guanine; 7-(alkyl)guanine; 7-(deaza)guanine; 7-(methyl)guanine; 8(alkyl)guanine; 8(alkynyl)guanine; 8(halo)guanine; 8(sulfanyl)guanine; 8-(alkenyl)guanine; 8-(alkyl)guanine; 8-(alkynyl)guanine; 8-(amino)guanine; 8-(halo)guanine; 8-(hydroxy)guanine; 8-(sulfanyl)guanine; 8-(thiol)guanine; azaguanine; deaza Guanine; N(methyl)guanine; N-(methyl)guanine; 1-methyl-6-thio-guanosine; 6-methoxy-guanosine; 6-thio-7-deaza-8-aza-guanosine; 6-thio-7-deaza-guanosine; 6-thio-7-methyl-guanosine; 7-deaza-8-aza-guanosine; 7-methyl-8-oxo-guanosine; N2,N2-di-methyl-6-thio-guanosine; N2-methyl-6-thio-guanosine; 1-Me-GTP; 2′fluoro-N2-isobutyl-guanosine TP; 2′O-methyl-N2-isobutyl-guanosine TP; 2′-a-ethynylguanosine TP; 2′-a-trifluoromethylguanosine TP; 2′-b-ethynylguanosine TP; 2′-b-trifluoromethylguanosine TP;2′-deoxy-2′,2′-difluoroguanosine TP; 2′-deoxy-2′-a-thioguanosine TP; 2′-deoxy-2′-a-thiomethoxyguanosine TP; 2′-deoxy-2′-b-aminoguanosine TP; 2′-deoxy-2′-b-azidoguanosine TP; 2′-deoxy-2′-b-bromoguanosine TP; 2′-deoxy-2′-b-chloroguanosine TP; 2′-deoxy-2′-b-fluoroguanosine TP; 2′-deoxy-2′-b-iodoguanosine TP; 2′-deoxy-2′-b-thioguanosine TP; 2′-deoxy-2′-b-thiomethoxyguanosine TP; 4′-azidoguanosine TP; 4′-carbocyclic guanosine TP; 4′-ethynylguanosine TP; 5′- Homo-guanosine TP; 8-bromo-guanosine TP; 9-deazaguanosine TP; N2-isobutyl-guanosine TP; 1-methylinosine; inosine; 1,2′-O-dimethylinosine; 2′-O-methylinosine; 7-methylinosine; 2′-O-methylinosine; Epoxyqueuosine; Galactosyl-Q nucleoside; Mannosyl Q nucleoside; Q nucleoside; Allylamino-thymidine; Azathymidine; Deazathymidine; Deoxy-thymidine; 2′-O-methyluridine; 2-thiouridine; 3-methyluridine; 5-carboxymethyluridine; 5-hydroxyuridine; 5-methyluridine; 5-taurinemethyl-2-thiouridine; 5-taurinemethyluridine; dihydrouridine; pseudouridine; (3-(3-amino-3- 1-methyl-3-(3-amino-5-carboxypropyl)uridine; 1-methyl-pseudouridine; 1-methyl-pseudouridine; 1-ethyl-pseudouridine; 2′-O-methyluridine; 2′-O-methyl-pseudouridine; 2′-O-methyluridine; 2-thio-2′-O-methyluridine; 3-(3-amino-3-carboxypropyl)uridine; 3,2′-O-dimethyluridine; 3-methyl-pseudouridine TP; 4-thiouridine; 5-(carboxyhydroxymethyl)uridine; 5-(carboxyhydroxymethyl)uridine methyl ester; 5,2′-O-dimethyluridine; 5,6-dihydro-uridine; 5-aminomethyl-2-thiouridine; 5-carbamoylmethyl-2′-O-methyluridine; 5-carbamoylmethyluridine; 5-carboxyhydroxymethyluridine; 5-carboxyhydroxymethyluridine methyl ester; 5-carboxymethylaminomethyl-2′-O-methyluridine; 5-carboxymethylaminomethyl-2-thiouridine; 5-carboxymethylaminomethyl-2-thiouridine; 5-carboxymethylaminomethyluridine; 5-carboxymethylaminomethyluridine; 5-carboxymethylaminomethyluridine; 5-carbamoylmethyluridine TP; 5-methoxycarbonylmethyl-2′-O-methyluridine; 5-methoxycarbonylmethyl-2-thiouridine; 5-methoxycarbonylmethyluridine; 5-methyluridine; 5-methoxyuridine; 5-methyl-2-thiouridine; 5-methylaminomethyl-2-selenoyluridine; 5-methylaminomethyl-2-thiouridine; 5-methylaminomethyluridine; 5-methyldihydrouridine; 5-oxyacetic acid-uridine TP; 5-oxyacetic acid-methyl ester-uridine TP;N1-methyl-pseudo-uracil; N1-ethyl-pseudo-uracil; uridine 5-oxyacetic acid; uridine 5-oxyacetic acid methyl ester; 3-(3-amino-3-carboxypropyl)-uridine TP; 5-(isopentenylaminomethyl)-2-thiouridine TP; 5-(isopentenylaminomethyl)-2′-O-methyluridine TP; 5-(isopentenylaminomethyl)uridine TP; 5-propynyluracil; α-thio-uridine; 1(aminoalkylaminocarbonylvinyl)-2(thio)-pseudouracil; 1(aminoalkylaminocarbonylvinyl)-2,4-(dithio)pseudouracil; 1(aminoalkylaminocarbonylvinyl)-4(thio)pseudouracil; 1(aminoalkylaminocarbonylvinyl)-pseudouracil; 1(aminocarbonyl 1-(aminoalkylamino-carbonylvinyl)-2-(thio)-pseudouracil; 1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine TP; 1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine TP; 1-methyl-pseudouridine TP; 1-methyl-pseudouridine TP; 1-ethyl-pseudouridine TP; 2-(thio)-pseudouridine TP; 1-ethyl-pseudouridine TP; 2-(thio)-pseudouridine TP; 1-methyl-pseudouridine TP; 1-ethyl-pseudouridine TP; 2-(thio)-pseudouridine TP; 1-ethyl-pseudouridine TP; 2-(thio)-pseudouridine TP; 1-ethyl-pseudouridine TP; 2-(thio)-pseudouridine TP; 1-ethyl-pseudouridine TP; 1-methyl-pseudouridine TP; 1-ethyl-pseudouridine TP; 2-(thio)-pseudouridine TP; 1-ethyl ... uridine; 2'deoxyuridine; 2'fluorouridine; 2-(thio)uracil; 2,4-(dithio)pseudouridine; 2'methyl, 2'amino, 2'azido, 2'fluoro-guanosine; 2'-amino-2'-deoxy-UTP; 2'-azido-2'-deoxy-UTP; 2'-azido-deoxyuridine TP; 2'-O-methylpseudouridine; 2'deoxyuridine; 2'fluorouridine; 2'-deoxy-2'-a-aminouridine TP; 2'-deoxy-2'-a-azidouridine TP; 2-methylpseudouridine; 3(3-amino-3-carboxypropyl)uracil; 4(thio)pseudouridine; 4-(thio)pseudouridine; 4-(thio)uracil; 4-thiouracil; 5(1,3-dithio)pseudouridine; oxazol-1-alkyl) uracil; 5(2-aminopropyl) uracil; 5(aminoalkyl) uracil; 5(dimethylaminoalkyl) uracil; 5(guanidinoalkyl) uracil; 5(methoxycarbonylmethyl)-2-(thio) uracil; 5(methoxycarbonyl-methyl) uracil; 5(methyl)2(thio) uracil; 5(methyl)2,4(dithio) uracil; 5(methyl)4(thio) uracil; 5(methylaminomethyl)-2(thio) uracil; 5(methylaminomethyl)-2,4(dithio) uracil; 5(methylaminomethyl)-4(thio) uracil; 5(propynyl) uracil; 5(trifluoromethyl) uracil; 5-(2-aminopropyl) uracil; 5-(alkyl)-2-(thio) pseudouracil;5-(Alkyl)-2,4(disulfide)pseudouracil; 5-(alkyl)-4(thio)pseudouracil; 5-(alkyl)pseudouracil; 5-(alkyl)uracil; 5-(alkynyl)uracil; 5-(allylamino)uracil; 5-(cyanoalkyl)uracil; 5-(dialkylaminoalkyl)uracil; 5-(dimethylaminoalkyl)uracil; 5-(guanidinoalkyl)uracil; 5-(halo)uracil; 5-(1,3-oxadiazol-1-alkyl)uracil; 5-(methoxy)uracil; 5-(methoxycarbonylmethyl)-2-(thio)uracil; 5-(methoxycarbonyl-methyl)uracil; 5-(methyl)2(thio)uracil; 5-(methyl)2,4(disulfide)uracil; 5-(methyl) 4(thio)uracil; 5-(methyl)-2-(thio)pseudouracil; 5-(methyl)-2,4(dithio)pseudouracil; 5-(methyl)-4(thio)pseudouracil; 5-(methyl)pseudouracil; 5-(methyl)pseudouracil; 5-(methylaminomethyl)-2(thio)uracil; 5-(methylaminomethyl)-2,4(dithio)uracil; 5-(methylaminomethyl)-4-(thio)uracil; 5-(propynyl)uracil; 5-(trifluoromethyl)uracil; 5-aminoallyl-uridine; 5-bromo-uridine; 5-iodo-uridine; 5-uracil; 6(azo)uracil; 6-(azo)uracil; 6-aza-uridine; allylamino-uracil; azauracil; deazauracil; N3(methyl) Uracil; pseudo-UTP-1-2-acetic acid; pseudouracil; 4-thio-pseudo-UTP; 1-carboxymethyl-pseudouridine; 1-methyl-1-deaza-pseudouridine; 1-propynyl-uridine; 1-taurinomethyl-1-methyl-uridine; 1-taurinomethyl-4-thio-uridine; 1-taurinomethyl-pseudouridine; 2-methoxy-4-thio-pseudouridine; 2-thio-1-methyl-1-deaza-pseudouridine; 2-thio-1-methyl-pseudouridine; 2-thio-5-aza-uridine; 2-thio-dihydropseudouridine; 2-thio-dihydrouridine; 2-thio-pseudouridine; 4-methoxy-2-thio-pseudouridine; 4-methoxy-pseudouridine; 4-thio-1-methyl-pseudouridine; 4-thio- Pseudouridine; 5-aza-uridine; dihydropseudouridine; (±)1-(2-hydroxypropyl)pseudouridine TP; (2R)-1-(2-hydroxypropyl)pseudouridine TP; (2S)-1-(2-hydroxypropyl)pseudouridine TP; (E)-5-(2-bromo-vinyl)arabino-uridine TP; (E)-5-(2-bromo-vinyl)uridine TP; (Z)-5-(2-bromo-vinyl)arabino-uridine TP; (Z)-5-(2-bromo-vinyl)uridine TP; 1-(2,2,2-trifluoroethyl)-pseudouridine TP; 1-(2,2,3,3,3-pentafluoropropyl)pseudouridine TP; 1-(2,2-diethoxyethyl)pseudouridine TP; 1-(2,4,6-trimethylbenzyl)pseudouridine TP;1-(2,4,6-trimethyl-benzyl) pseudo-UTP; 1-(2,4,6-trimethyl-phenyl) pseudo-UTP; 1-(2-amino-2-carboxyethyl) pseudo-UTP; 1-(2-amino-ethyl) pseudo-UTP; 1-(2-hydroxyethyl) pseudo-uridine TP; 1-(2-methoxyethyl) pseudo-uridine TP; 1-(3,4-bis-trifluoromethoxybenzyl) pseudo-uridine TP; 1-(3,4-dimethoxybenzyl) pseudo-uridine TP; 1-(3-amino-3-carboxypropyl) pseudo-UTP; 1-(3-amino-propyl) pseudo-UTP; 1-(3-cyclopropyl-prop-2-ynyl) pseudo-uridine TP; 1-(4-amino-4-carboxybutyl) pseudo-UTP; 1-(4-amino-benzyl) pseudo-UTP 1-(4-amino-butyl) pseudo-UTP; 1-(4-amino-phenyl) pseudo-UTP; 1-(4-azidobenzyl) pseudouridine TP; 1-(4-bromobenzyl) pseudouridine TP; 1-(4-chlorobenzyl) pseudouridine TP; 1-(4-fluorobenzyl) pseudouridine TP; 1-(4-iodobenzyl) pseudouridine TP; 1-(4-methylsulfonylbenzyl) pseudouridine TP; 1-(4-methoxybenzyl) pseudouridine TP; 1-(4-methoxy-benzyl) pseudo-UTP; 1-(4-methoxy-phenyl) pseudo-UTP; 1-(4-methylbenzyl) pseudouridine TP; 1-(4-methyl-benzyl) pseudo-UTP; 1-(4-nitrobenzyl) pseudouridine TP; 1-(4-nitrobenzyl) pseudouridine 1-(4-thiomethoxybenzyl) pseudo-UTP; 1-(4-trifluoromethoxybenzyl) pseudo-UTP; 1-(4-trifluoromethylbenzyl) pseudo-UTP; 1-(5-amino-pentyl) pseudo-UTP; 1-(6-amino-hexyl) pseudo-UTP; 1,6-dimethyl-pseudo-UTP; 1-[3-(2-{2-[2-(2-aminoethoxy)-ethoxy]-ethoxy}-ethoxy)-propionyl] pseudo-UTP; 1-{3-[2-(2-aminoethoxy)-ethoxy]-propionyl} pseudo-UTP; 1-acetyl pseudo-UTP; 1-alkyl-6-(1-propynyl)-pseudo-UTP; 1-alkyl-6 -(2-propynyl)-pseudo-UTP; 1-alkyl-6-allyl-pseudo-UTP; 1-alkyl-6-ethynyl-pseudo-UTP; 1-alkyl-6-homoallyl-pseudo-UTP; 1-alkyl-6-vinyl-pseudo-UTP; 1-allyl pseudouridine TP; 1-aminomethyl-pseudo-UTP; 1-benzoyl pseudouridine TP; 1-benzyloxymethyl pseudouridine TP; 1-benzyl-pseudo-UTP; 1-biotinyl-PEG2-pseudouridine TP; 1-biotinyl pseudouridine TP; 1-butyl-pseudo-UTP; 1-cyanomethyl pseudouridine TP; 1-cyclobutylmethyl-pseudo-UTP; 1-cyclobutyl-pseudo-UTP; 1-cycloheptylmethyl-pseudo-UTP; 1-cycloheptyl-pseudo-UTP;1-cyclohexylmethyl-pseudo-UTP; 1-cyclohexyl-pseudo-UTP; 1-cyclooctylmethyl-pseudo-UTP; 1-cyclooctyl-pseudo-UTP; 1-cyclopentylmethyl-pseudo-UTP; 1-cyclopentyl-pseudo-UTP; 1-cyclopropylmethyl-pseudo-UTP; 1-cyclopropyl-pseudo-UTP; 1-ethyl-pseudo-UTP; 1-hexyl-pseudo-UTP; 1-homoallyl pseudouridine TP; 1-hydroxymethyl pseudouridine TP; 1-iso-propyl pseudo-UTP; 1-Me-2-thio-pseudo-UTP; 1-Me-4-thio-pseudo-UTP; 1-Me-α-thio-pseudo-UTP; 1-methylsulfonylmethyl pseudouridine TP; 1-methoxymethyl pseudouridine TP; 1-methyl-6-(2,2,2 -trifluoroethyl) pseudo-UTP; 1-methyl-6-(4-morpholinyl)-pseudo-UTP; 1-methyl-6-(4-thiomorpholinyl)-pseudo-UTP; 1-methyl-6-(substituted phenyl) pseudo-UTP; 1-methyl-6-amino-pseudo-UTP; 1-methyl-6-azido-pseudo-UTP; 1-methyl-6-bromo-pseudo-UTP; 1-methyl-6-butyl-pseudo-UTP; 1-methyl-6-chloro-pseudo-UTP; 1-methyl-6-cyano-pseudo-UTP; 1-methyl-6-dimethylamino-pseudo-UTP; 1-methyl-6-ethoxy-pseudo-UTP; 1-methyl-6-carboxylic acid ethyl ester-pseudo-UTP; 1-methyl-6-ethyl-pseudo-UTP; 1-methyl-6-fluoro- pseudo-UTP; 1-methyl-6-formyl-pseudo-UTP; 1-methyl-6-hydroxyamino-pseudo-UTP; 1-methyl-6-hydroxy-pseudo-UTP; 1-methyl-6-iodo-pseudo-UTP; 1-methyl-6-iso-propyl-pseudo-UTP; 1-methyl-6-methoxy-pseudo-UTP; 1-methyl-6-methylamino-pseudo-UTP; 1-methyl-6-phenyl-pseudo-UTP; 1-methyl-6-propyl-pseudo-UTP; 1-methyl-6-tert-butyl-pseudo-UTP; 1-methyl-6-trifluoromethoxy-pseudo-UTP; 1-methyl-6-trifluoromethyl-pseudo-UTP; 1-morpholinomethyl pseudouridine TP; 1-pentyl-pseudo-UTP; 1-phenyl-pseudo-UTP; 1-trimethyl 1-acetyl pseudouridine TP; 1-propynyl pseudouridine TP; 1-propyl-pseudo-UTP; 1-propynyl-pseudouridine; 1-p-tolyl-pseudo-UTP; 1-tert-butyl-pseudo-UTP; 1-thiomethoxymethyl pseudouridine TP; 1-thiomorpholinylmethyl pseudouridine TP; 1-trifluoroacetyl pseudouridine TP; 1-trifluoromethyl-pseudo-UTP; 1-vinyl pseudouridine TP; 2,2′-anhydro-uridine TP; 2′-bromo-deoxyuridine TP; 2′-F-5-methyl-2′-deoxy-UTP; 2′-OMe-5-MeUTP; 2′-OMe-pseudo-UTP; 2′-a-ethynyl uridine TP; 2′-a-trifluoromethyl uridine TP; 2′-b-ethynyl uridine TP;2′-b-trifluoromethyluridine TP; 2′-deoxy-2′,2′-difluorouridine TP; 2′-deoxy-2′-a-thiouridine TP; 2′-deoxy-2′-a-thiomethoxyuridine TP; 2′-deoxy-2′-b-aminouridine TP; 2′-deoxy-2′-b-azidouridine TP; 2′-deoxy-2′-b-bromouridine TP; 2′-deoxy-2′-b-chlorouridine TP; 2′-deoxy-2′-b-fluorouridine TP; 2′-deoxy-2′-b-iodouridine TP; 2′-deoxy-2′-b-thiouridine TP; 2′-deoxy-2′-b-thiouridine TP; 2′-deoxy-2′ -b-Thiomethoxyuridine TP; 2-methoxy-4-thio-uridine; 2-methoxyuridine; 2′-O-methyl-5-(1-propynyl)uridine TP; 3-alkyl-pseudo-UTP; 4′-azidouridine TP; 4′-carbocyclic uridine TP; 4′-ethynyl uridine TP; 5-(1-propynyl)arabino-uridine TP; 5-(2-furanyl)uridine TP; 5-cyanouridine TP; 5-dimethylaminouridine TP; 5′-homo-uridine TP; 5-iodo-2′-fluoro-deoxyuridine TP; 5-phenylethynyl uridine TP; 5-trideuteromethyl-6-deuterouidine TP; 5-trifluoromethyl-uridine TP; 5-vinyl arabinouridine TP; 6-(2,2,2-trifluoroethyl)-pseudo-UTP; 6-(4-morpholinyl)-pseudo-UTP; 6-(4-thiomorpholinyl)-pseudo-UTP; 6-(substituted phenyl)-pseudo-UTP; 6-amino-pseudo-UTP; 6-azido-pseudo-UTP; 6-bromo-pseudo-UTP; 6-butyl-pseudo-UTP; 6-chloro-pseudo-UTP; 6-cyano-pseudo-UTP; 6-dimethylamino-pseudo-UTP; 6-ethoxy-pseudo-UTP; 6-carboxylic acid ethyl ester-pseudo-UTP; 6-ethyl-pseudo-UTP; 6-fluoro-pseudo-UTP; 6-methyl Acyl-pseudo-UTP; 6-hydroxyamino-pseudo-UTP; 6-hydroxy-pseudo-UTP; 6-iodo-pseudo-UTP; 6-iso-propyl-pseudo-UTP; 6-methoxy-pseudo-UTP; 6-methylamino-pseudo-UTP; 6-methyl-pseudo-UTP; 6-phenyl-pseudo-UTP; 6-phenyl-pseudo-UTP; 6-propyl-pseudo-UTP; 6-tert-butyl-pseudo-UTP; 6-trifluoromethoxy-pseudo-UTP; 6-trifluoromethyl-pseudo-UTP; α-thio-pseudo-UTP; pseudouridine 1-(4-methylbenzenesulfonic acid) TP; pseudouridine 1-(4-methylbenzoic acid) TP; pseudouridine TP 1-[3-(2-ethoxy)]propionic acid; pseudouridine TP 1-[3-{2-(2-[2-(2-ethoxy)-ethoxy]-ethoxy)-ethoxy}]propionic acid; pseudouridine TP 1-[3-{2-(2-[2-{2(2-ethoxy)-ethoxy}-ethoxy]-ethoxy)-ethoxy}]propionic acid;Pseudouridine TP 1-[3-{2-(2-[2-ethoxy]-ethoxy)-ethoxy}]propionic acid; Pseudouridine TP 1-[3-{2-(2-ethoxy)-ethoxy}]propionic acid; Pseudouridine TP 1-methylphosphonic acid; Pseudouridine TP 1-methylphosphonic acid diethyl ester; pseudo-UTP-N1-3-propionic acid; pseudo-UTP-N1-4-butyric acid; pseudo-UTP-N1-5-pentanoic acid; pseudo-UTP-N1-6-hexanoic acid; pseudo-UTP-N1-7-heptanoic acid; pseudo-UTP-N1-methyl-p-benzoic acid; pseudo-UTP-N1-p-benzoic acid; Wybutosine; hydroxy Wybutosine; isowybutosine; peroxy Wybutosine; incompletely modified hydroxy Wybutosine; 4-demethyl Wybutosine; 2,6-(diamino)purine; 1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl; 1,3-(diaza)-2-(side-oxy) )-phenothiazin-1-yl; 1,3-(diaza)-2-(oxo)-phenothiazin-1-yl; 1,3,5-(triaza)-2,6-(dioxa)-naphthalene; 2(amino)purine; 2,4,5-(trimethyl)phenyl; 2′methyl, 2′amino, 2′azido, 2′fluoro-cytidine; 2′methyl, 2′amino, 2′azido, 2′fluoro-adenine; 2′methyl, 2′amino, 2′azido, 2′fluoro-uridine; 2′-amino-2′-deoxyribose; 2-amino-6-chloro-purine; 2-aza-inosyl; 2′-azido-2′-deoxyribose; 2′fluoro-2′-deoxyribose; 2′ -Fluoro-modified bases; 2′-O-methyl-ribose; 2-oxo-7-aminopyridopyrimidin-3-yl; 2-oxo-pyridopyrimidin-3-yl; 2-pyridone; 3-nitropyrrole; 3-(methyl)-7-(propynyl)isoquinolone; 3-(methyl)isoquinolone; 4-(fluoro)-6-(methyl)benzimidazole; 4-(methyl)benzimidazole; 4-(methyl)indolyl; 4,6-(dimethyl)indolyl; 5-nitroindole; 5-substituted pyrimidine; 5-(methyl)isoquinolone; 5-nitroindole; 6-(aza)pyrimidine; 6-(azo)thymine; 6-(methyl)-7-(aza)indolyl; 6-chloro- Purine; 6-phenyl-pyrrolo-pyrimidin-2-one-3-yl; 7-(aminoalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenothiazin-1-yl; 7-(aminoalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenothiazin-1-yl; 7-(aminoalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenothiazin-1-yl; 7-(aminoalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenothiazin-1-yl; 7-(aminoalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenothiazin-1-yl; 7-(aminoalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenothiazin-1-yl; 7-(aza)indolyl;7-(Guanidinoalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl; 7-(Guanidinoalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl; 7-(Guanidinoalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl; 7-(Guanidinoalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenoxazin-1-yl; 7-(Guanidinoalkyl-hydroxy)-1,3-(diaza)-2-(oxo)-phenoxazin-1-yl; 7-(Guanidinoalkyl-hydroxy)-1,3-(diaza)-2-(oxo)-phenoxazin-1-yl ; 7-(propynyl)isoquinolone; 7-(propynyl)isoquinolone; propynyl-7-(aza)indolyl; 7-deaza-inosinyl; 7-substituted 1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl; 7-substituted 1,3-(diaza)-2-(oxo)-phenoxazin-1-yl; 9-(methyl)-imidazopyridinyl; aminoindolyl; anthracenyl; bis-o-(aminoalkylhydroxy)-6-phenyl-pyrrolo-pyrimidin-2-one-3-yl; bis-o-substituted 6-phenyl-pyrrolo-pyrimidin-2-one-3-yl; difluorotolyl; hypoxanthine; imidazopyridinyl; inosinyl; isoquinolone; isoguanosine; N 2-Substituted Purine; N6-Methyl-2-amino-purine; N6-Substituted Purine; N-Alkylated Derivatives; Naphthyl; Nitrobenzimidazolyl; Nitroimidazolyl; Nitroindazolyl; Nitropyrazolyl; Nubularine; O6-Substituted Purine; O-Alkylated Derivatives; o-(aminoalkylhydroxy)-6-phenyl-pyrrolo-pyrimidin-2-one-3-yl; o-Substituted 6-phenyl-pyrrolo-pyrimidin-2-one-3-yl; Oxoformycin TP; p-(aminoalkylhydroxy)-6-phenyl-pyrrolo-pyrimidin-2-one-3-yl; p-Substituted 6-phenyl-pyrrolo-pyrimidin -2-keto-3-yl; pentacene; benzanthryl; phenyl; propynyl-7-(aza)indolyl; pyrenyl; pyridopyrimidin-3-yl; pyridopyrimidin-3-yl; 2-oxo-7-amino-pyridopyrimidin-3-yl; pyrrolo-pyrimidin-2-keto-3-yl; pyrrolopyrimidinyl; pyrrolopyrazinyl; stilbene; substituted 1,2,4-triazole; tetraphenyl; tuberculocidin; xanthine; xanthine riboside-5′-TP; 2-thio-zebularine; 5-aza-2-thio-zebularine; 7-deaza-2-amino-purine; pyridine-4-one ribonucleoside; 2-amino-riboside-TP; metopromycin A TP; mesomorphin B TP; pyrrolosine TP; 2′-OH-arabino-adenosine TP; 2′-OH-arabino-cytosine TP; 2′-OH-arabino-uridine TP;2′-OH-arabino-guanosine TP; 5-(2-methoxycarbonylvinyl)uridine TP; and N6-(19-amino-pentaoxanonadecanyl)adenosine TP. ;

[0223] In one embodiment, the vaccine is a protein vaccine, which comprises the gE protein antigen variant described above.

[0224] Furthermore, the protein vaccine is carried by a carrier, which includes serum albumin, immunoglobulin molecules, thyroglobulin, ovalbumin, tetanus toxoid, diphtheria toxoid, genetically modified cross-reactive substances of diphtheria toxoid, CRM197, meningococcal outer membrane protein complex and Haemophilus influenzae protein D, rEPA, keyhole limpet hemocyanin, and / or flagellin.

[0225] Furthermore, the protein vaccine is presented by a variety of antigen presentation systems.

[0226] Furthermore, the antigen presentation system comprises one or more of a Lys-based dendritic structure, a helper T cell epitope, an immunostimulatory lipophilic moiety, a cell penetrating peptide, free radical-induced polymerization, self-assembled nanoparticles and gold nanoparticles.

[0227] In one embodiment, the vaccine is a viral vector vaccine, which comprises a nucleotide sequence encoding an open reading frame of at least one of the aforementioned gE protein antigen variants.

[0228] Furthermore, the nucleotide sequence is codon-optimized or codon-degenerate.

[0229] Further, the nucleotide sequence is codon selected to be changed from the natural type. Any suitable viral vector can be used for the construction of the vaccine of the present invention, and suitable viral vectors have been described in Dicks et al. (Vaccine. February 25, 2015; 33 (9): 1121-8.doi: 10.1016 / j.vaccine.2015.01.042.Epub January 25, 2015), Antrobus et al. (Mol Ther. 2014 Mar; 22 (3): 668-74.doi: 10.1038 / mt.2013.284.Epub December 30, 2013) and Warimwe et al. (Virol J. December 5, 2013; 10: 349.doi: 10.1186 / 1743-422X-10-349), which are incorporated herein by reference.

[0230] Furthermore, the vectors in the viral vector vaccine self-assemble into virus-like particles.

[0231] Furthermore, the vector includes a self-inactivating vector.

[0232] Furthermore, the virus is selected from lentivirus, influenza virus, hepatitis virus, alphavirus, filovirus, adenovirus, adeno-associated virus and / or flavivirus.

[0233] Furthermore, the virus is an adenovirus or an adeno-associated virus.

[0234] Further, the virus is an adenovirus; for example, a human, monkey or chimpanzee adenovirus. In one embodiment, the viral vector comprises an adenovirus, such as a group E monkey adenovirus. The viral vector may comprise ChAdOx1 or ChAdOx2. The viral vector may comprise AdCh63. The viral vector may comprise AdC3 or AdH6. In one embodiment, the viral vector is a human serotype.

[0235] In some embodiments of the invention, the vaccine further comprises gI, gB, gH, gK, gL, gC, gN and / or gM glycoproteins of varicella zoster virus. In some embodiments, the vaccine may be any combination of VZV gE and at least one of gI, gB, gH, gK, gL, gC, gN and gM polypeptides or immunogenic fragments or epitopes thereof. In some embodiments, the vaccine may be any combination of VZV gE, gI and at least one of gB, gH, gK, gL, gC, gN and gM polypeptides or immunogenic fragments or epitopes thereof.

[0236] In an embodiment of the present invention, the vaccine further comprises a pharmaceutically acceptable adjuvant.

[0237] Furthermore, the pharmaceutically acceptable adjuvants include adjuvants required for intravenous drip, subcutaneous injection, intravenous push injection, intravitreal injection, and intramuscular injection.

[0238] Furthermore, the adjuvant includes physiological saline, solution tension regulator, solution osmotic pressure regulator, viscosity reducing adjuvant, buffer or surfactant.

[0239] Furthermore, the solution tension regulator includes sodium chloride or arginine.

[0240] Furthermore, the solution osmotic pressure regulator includes sucrose, trehalose, sorbitol or mannitol.

[0241] Furthermore, the viscosity reducing adjuvant includes arginine, sodium chloride, glycine, proline or lysine.

[0242] Furthermore, the buffer comprises histidine, phosphate, citric acid, acetate, succinic acid, lactic acid, tromethamine, aspartic acid, glutamic acid, adipic acid or MES.

[0243] Furthermore, the surfactant includes polysorbate 20, polysorbate 80, poloxamer 188 or polyethylene glycol 3350.

[0244] The term "pharmaceutically acceptable" designates that the carrier is generally chemically and / or physically compatible with the other ingredients making up the formulation and physiologically compatible with the recipient thereof. Pharmaceutically acceptable adjuvants used in the vaccine compositions of the present invention may include, but are not limited to, for example, pharmaceutically acceptable liquids, gels or solid carriers, aqueous vehicles (e.g., sodium chloride injection, Ringer's injection, isotonic dextrose injection, sterile water injection or Ringer's dextrose and lactate injection), non-aqueous vehicles (e.g., non-volatile oils of plant origin, cottonseed oil, corn oil, sesame oil or peanut oil), antimicrobial agents, isotonic agents (e.g., sodium chloride or dextrose), buffers (e.g., phosphate or citrate buffer), antioxidants (e.g., sodium bisulfate), anesthetics (e.g., procaine hydrochloride), suspending / dispersing agents (e.g., sodium carboxymethylcellulose, hydroxypropyl methylcellulose or polyvinylpyrrolidone), chelating agents (e.g., EDTA (ethylenediaminetetraacetic acid) or EGTA (ethylene glycol tetraacetic acid)), emulsifiers (e.g., polysorbate 80 (Tween 80)), diluents, adjuvants, excipients, or non-toxic auxiliary substances, other components known in the art, or various combinations thereof. Suitable components may include, for example, fillers, binders, disintegrants, buffers, preservatives, lubricants, flavoring agents, thickeners, colorants or emulsifiers.

[0245] In embodiments of the present invention, the term "vaccine" is defined as a composition used to elicit or stimulate an immune response against an antigen or fragment thereof within the composition to protect or treat an organism from a disease.

[0246] The present invention provides a derivative of a gE protein antigen variant, wherein the derivative comprises a complex formed by directly or indirectly coupling the aforementioned gE protein antigen variant to a detectable marker.

[0247] Furthermore, the detectable label includes fluorescent dyes, chemiluminescent compounds, radioactive isotopes, electron-dense reagents, enzymes, colored particles, or biotin.

[0248] In the present invention, the term "derivative" can be a nucleic acid molecule, as a DNA molecule, encoding a polynucleotide as defined above, or a nucleic acid molecule comprising a polynucleotide as defined above, or a polynucleotide of a complementary sequence. In the context of the present invention, the term "derivative" also refers to a longer or shorter polynucleotide and / or polypeptide having, for example, at least 40%, 50%, 60%, 65%, 70% or 75%, more preferably at least 85%, for example at least 90%, even more preferably at least 95% or 100% identity percentage with the sequence mentioned or its complementary sequence or its DNA or RNA corresponding sequence. The term "derivative" also includes modified synthetic oligonucleotides. The term "derivative" may also include nucleotide analogs, i.e., naturally occurring ribonucleotides or deoxyribonucleotides substituted by non-naturally occurring nucleotides. The term "derivative" also includes nucleic acids or polypeptides that can be produced by mutating one or more nucleotides or amino acids in its sequence, equivalent or precursor sequence. The term "derivative" also includes at least one functional fragment of a polynucleotide.

[0249] The term "detectable marker" refers to an agent detectable by spectroscopy, photochemistry, biochemistry, immunochemistry or chemical means. Useful detectable markers include, but are not limited to, fluorescent dyes, chemiluminescent compounds, radioisotopes, electron-dense reagents, enzymes, colored particles, biotin. Detectable markers tend to produce measurable signals, such as radioactivity, fluorescence, color or enzyme activity. Antibodies coupled to detectable agents can be used for diagnostic or therapeutic purposes. Examples of detectable agents include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals using various positron emission tomography, and non-radioactive paramagnetic metal ions. Detectable substances can be directly connected or coupled to antibodies using techniques known in the art, or indirectly through intermediates such as joints known in the art. See, U.S. Patent No. 4,741,900, which describes the coupling of metal ions to antibodies for diagnosis. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, and acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin / biotin and avidin / biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazineamine fluorescein, dansyl chloride, and phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferin and photoluminescent protein.

[0250] The present invention provides the use of the above-mentioned gE protein antigen variant in the preparation of a product for detecting varicella-zoster virus.

[0251] The present invention provides the use of the aforementioned gE protein antigen variant in preparing, capturing or screening antibodies that recognize varicella zoster virus gE protein.

[0252] The term "antibody" includes heterotetrameric glycoproteins of about 150,000 daltons with identical structural features, consisting of two identical light chains (L) and two identical heavy chains (H). Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide bonds varies between heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bonds. Each heavy chain has a variable region (VH) at one end. This is followed by multiple constant regions. Each light chain has a variable region (VL) at one end and a constant region at the other end; the constant region of the light chain is opposite to the first constant region of the heavy chain, and the variable region of the light chain is opposite to the variable region of the heavy chain. Specific amino acid residues form an interface between the variable regions of the light and heavy chains.

[0253] The present invention provides the use of the aforementioned gE protein antigen variant, the aforementioned nucleic acid molecule, the aforementioned vector, the aforementioned cell, the aforementioned pharmaceutical composition or the aforementioned vaccine in the preparation of a product for treating or preventing varicella-zoster virus-related diseases.

[0254] The present invention provides the use of the aforementioned gE protein antigen variant, the aforementioned nucleic acid molecule, the aforementioned vector, the aforementioned cell, the aforementioned pharmaceutical composition or the aforementioned vaccine in the preparation of a product for inhibiting varicella-zoster virus.

[0255] The present invention provides the use of the aforementioned gE protein antigen variant, the aforementioned nucleic acid molecule, the aforementioned vector, the aforementioned cell, the aforementioned pharmaceutical composition or the aforementioned vaccine in the preparation of anti-gE protein antibodies.

[0256] The present invention provides a method for screening, detecting or isolating antibodies to varicella-zoster virus gE protein, which comprises using the aforementioned gE protein antigen variant to screen, detect or isolate antibodies to varicella-zoster virus gE protein.

[0257] The present invention provides a method for producing the aforementioned gE protein antigen variant, the method comprising the following steps:

[0258] (i) using the aforementioned vector to transform into a host cell, or directly using the aforementioned cell;

[0259] (ii) culturing the host cell or cells in step (i) under suitable conditions;

[0260] (iii) isolating and purifying the aforementioned gE protein antigen variant from the host cell culture fluid.

[0261] The present invention provides a detection reagent, a test paper and a kit containing the same, which contains the aforementioned gE protein antigen variant, the aforementioned nucleic acid molecule, the aforementioned vector, the aforementioned cell, the aforementioned pharmaceutical composition or the aforementioned derivative.

[0262] A method of inhibiting or reducing varicella zoster virus in a subject suffering from or at risk of developing a varicella zoster virus-associated disease, comprising the step of administering to the subject the vaccine described above.

[0263] A method for inducing an immune response in a subject, the method comprising delivering the aforementioned gE protein antigen variant, the aforementioned nucleic acid molecule, the aforementioned vector, the aforementioned pharmaceutical composition and / or the aforementioned vaccine in an amount sufficient to induce an immune response in a human.

[0264] Furthermore, the immune response includes an antigen-specific immune response.

[0265] Furthermore, the antigen-specific immune response includes a T cell response or a B cell response.

[0266] Further, the subject is administered a single dose of the aforementioned vaccine.

[0267] Further, the subject is administered a first dose and a second dose (ie, a booster dose) of the aforementioned vaccine.

[0268] Furthermore, the method administers the vaccine to the subject by intravenous drip, subcutaneous injection, intravenous push injection, intravitreal injection, or intramuscular injection.

[0269] A method for preventing or treating varicella-zoster virus infection, comprising administering the above-described vaccine to a subject.

[0270] Beneficial effects of the present invention:

[0271] The present invention is an antigen variant of the varicella zoster virus gE protein, which exhibits high expression levels and high immunogenicity. Therefore, when the antigen variant is used as a vaccine composition, the vaccine composition has better safety compared to attenuated live vaccines; compared to the antigen of a recombinant protein vaccine, it has a high expression level on the cell membrane surface and exhibits better immunogenicity, and can be designed as a safer viral vector vaccine or an RNA vaccine with better immunogenicity for the prevention of herpes zoster. BRIEF DESCRIPTION OF THE DRAWINGS

[0272] Figure 1 This is the expression diagram of gE on the cell membrane surface detected by flow cytometry;

[0273] Figure 2 is the expression graph of gE detected by Western-blot;

[0274] Figure 3 This is the result of detecting the integrity of mRNA by agarose gel electrophoresis;

[0275] Figure 4 It is a flow cytometry analysis of the expression levels of different antigen variants on the cell membrane surface;

[0276] Figure 5 It is a picture of the immune assessment results;

[0277] Figure 6 This is a graph showing the test results of the immune effects of mRNA-gE truncated vaccine and other vaccines;

[0278] Figure 7 This is a graph showing the immune effect test results of adenovirus gE truncated vaccine and other vaccines. DETAILED DESCRIPTION

[0279] The present invention is further described below in conjunction with the embodiments. The following description is only a preferred embodiment of the present invention, and does not limit the present invention in other forms. Any technician familiar with the profession may use the above disclosed technical content to change it into an equivalent embodiment with equivalent changes. Any simple modification or equivalent change made to the following embodiments based on the technical essence of the present invention without departing from the content of the present invention falls within the protection scope of the present invention.

[0280] Example 1

[0281] 1. Construction of gE antigen variants

[0282] The C-terminus of the gE antigen was regularly truncated, and the desired gE fragments were obtained by PCR, and then each gE fragment was cut with a restriction endonuclease and inserted into the pCAGGS vector. After sequencing and identification, the DNA of the pCAGGS vector of the gE fragments of different variants was obtained by a plasmid extraction kit.

[0283] The amino acid sequences of the gE antigen variants are shown in Table 1.

[0284] Table 1

[0285] VZV gE antigen variants Variant features Sequence number 546 Truncate the carboxyl terminus at amino acid residue 546 GSK vaccine sequence 547 Truncate the carboxyl terminus at amino acid residue 547 SEQ ID NO:2 551 Truncate the carboxyl terminus at amino acid residue 551 SEQ ID NO:3 556 Truncate the carboxyl terminus at amino acid residue 556 SEQ ID NO:4 561 Truncate the carboxyl terminus at amino acid residue 561 SEQ ID NO:5 566 Truncate the carboxyl terminus at amino acid residue 566 SEQ ID NO:6 571 Truncate the carboxyl terminus at amino acid residue 571 SEQ ID NO:7 576 Truncate the carboxyl terminus at amino acid residue 576 SEQ ID NO:8 581 Truncate the carboxyl terminus at amino acid residue 581 SEQ ID NO:9 586 Truncate the carboxyl terminus at amino acid residue 586 SEQ ID NO:10 591 Truncate the carboxyl terminus at amino acid residue 591 SEQ ID NO:11 596 Truncate the carboxyl terminus at amino acid residue 596 SEQ ID NO:12 601 Truncate the carboxyl terminus at amino acid residue 601 SEQ ID NO:13 606 Truncate the carboxyl terminus at amino acid residue 606 SEQ ID NO:14 611 Truncate the carboxyl terminus at amino acid residue 611 SEQ ID NO:15 616 Truncate the carboxyl terminus at amino acid residue 616 SEQ ID NO:16 621 Truncate the carboxyl terminus at amino acid residue 621 SEQ ID NO:17 623 Truncate the carboxyl terminus at amino acid residue 623 SEQ ID NO:18

[0286] 2. Transient transfection of 293T cells

[0287] Inoculate cells one day before transfection, so that the cell density at the time of transfection is preferably 70% to 80%. For each well of cells, dilute 2μg of target DNA with 100μL serum-free medium and mix thoroughly to make a DNA dilution solution. Immediately add 4μL of PEI 40000 transfection reagent to 100μL of DNA dilution solution, vortex for 10 seconds, and mix thoroughly. Incubate at room temperature for 10 to 15 minutes to form a DNA-PEI cationic nucleic acid transfection reagent complex. Directly add 100μL of DNA-PEI nucleic acid-PEI complex to the cells, shake the culture plate, and gently mix. Incubate at 37℃, 5% CO2 incubator for 36 hours.

[0288] 3. Flow cytometry detection of gE expression on the cell membrane surface

[0289] Take 1×10 6 Add 50 μl of primary antibody (gE extracellular domain protein mouse immune serum) to the cell suspension, resuspend and incubate on ice in the dark for 30 minutes. After centrifugation, resuspend the cells in 200 μl of cell buffer and wash twice. Resuspend the pellet in 50 μl of cell buffer containing secondary antibody (FITC anti-mouse IgG Antibody) and incubate on ice in the dark for 30 minutes. After centrifugation, resuspend the cells in 200 μl of cell buffer and wash twice. Resuspend to 200 μl of cell buffer and perform flow cytometry analysis.

[0290] Flow cytometry analysis results Figure 1 As shown, the results showed that there was no combination of 546 / 547 truncations, the proportion of 551 truncations was significantly higher than the others, and the overall 591 truncation was the dividing point, and the proportion of truncations before 591 was basically higher than that after 591.

[0291] 4. Western-blot detection of gE expression

[0292] The cells were harvested and centrifuged at 350 x g for 5 minutes, resuspended in PBS and centrifuged, and then the intracellular samples were resuspended in 200 μl RIPA lysis buffer. The intracellular samples were subjected to Western Blot assay to confirm their correct expression.

[0293] The laboratory-made gE protein mouse immune serum was used as the primary antibody for detection. The results are as follows Figure 2 As shown, the results showed that the target bands were detected in all truncated forms.

[0294] 5. mRNA Preparation

[0295] Preparation of mRNA transcription template

[0296] After adding T7 promoter, 5'UTR and 3'UTR sequences to different antigen variant sequences of VZV gE nucleotides, the obtained DNA sequence was cloned into pUC57 vector and used as mRNA transcription template. After sequencing was correct, plasmid was extracted. Then, restriction endonuclease Hind III was used to linearize the transcription template plasmid, and the linearized transcription template was recovered using DNA magnetic beads.

[0297] Preparation of mRNA stock solution

[0298] mRNA transcription was performed according to the Vazyme T7 High Yield RNA Transcription Kit (N1-Me-Pseudo UTP), and the transcription conditions were incubated at 37 for 2 hours. After the transcription was completed, 1 μl of DNase I was added to the reaction system and incubated at 37°C for 15 minutes to digest the transcribed DNA template. The transcribed RNA was purified using VAHTS RNA purification magnetic beads, and the yield of in vitro transcribed RNA was determined by measuring the product A260 reading. The higher-order structure of the RNA 5' end was opened by thermal denaturation (heating at 65°C for 5 minutes and placing on ice for 5 minutes), and then the transcribed mRNA was capped using Vaccinia Capping Enzyme and 2'-O-Methyltransferase to form a cap1 cap. E. coli Poly(A) Polymerase+ was then used to add a polyadenylation tail to the 3' end of the mRNA. After capping and tailing, magnetic bead purification was performed, and the purified sample after tailing was the mRNA stock solution.

[0299] 6. Detection of mRNA stock solution

[0300] The integrity of mRNA was detected by Urea-TBE agarose gel electrophoresis. Figure 3 As shown, the results showed that the mRNA had good integrity and a single band.

[0301] Flow cytometry surface staining was used to determine the expression levels of different antigen variants on the cell membrane surface. Different truncated gE-mRNAs were transfected into 293T cells, and surface flow cytometry was performed 36 hours later. The primary antibody was V5 protein 3 rabbit serum, and the secondary antibody was FITC anti-mouse IgG Antibody.

[0302] The results are as follows Figure 4 As shown, the results showed that gE-mRNAs with different truncations were successfully expressed after transfection, and the trends of the mRNA transfection results were basically consistent with those of the plasmid transfection results.

[0303] 7. Preparation of mRNA-LNP

[0304] The mRNA was packaged into nanoparticles using microfluidics. The aqueous phase used was mRNA, and the concentration of mRNA-gE was 150 μg / ml (50 mM sodium acetate buffer solution, pH 4.0). The ethanol phase was a lipid mixture, prepared by ALC-0315, ALC-0159, DSPC and cholesterol in a molar ratio of 46.3:9.4:42.7:1.6. The instrument used for packaging was Myanna INanoL. During packaging, the total flow rate of the aqueous phase and the ethanol phase was 12 ml / min, the volume ratio of the ethanol phase to the aqueous phase was 1:3, and the flow rate ratio was 1:3. For the packaged mRNA-gE nanoparticles, the buffer was replaced with PBS using a 30 kDa ultrafiltration concentrator to obtain mRNA-gE-LNP, i.e., the vaccine composition.

[0305] 8. Testing of vaccine composition

[0306] The obtained mRNA vaccine compositions were used to detect the particle size, polydispersity index PDI and Zeta potential of LNP using the nanoparticle size detector Zetasizer Nano ZS. The LNP nanoparticle vaccine was incubated in 2% Triton-TE Buffer at room temperature for 10 minutes, and the nucleic acid concentration was detected using the nucleic acid detection kit Quant-iT RiboGreenR RNA Reagent Kit and the nucleic acid loading efficiency was calculated.

[0307] The physical and chemical properties of VZV gE mRNA-LNPs with different truncations were tested, including particle size, particle size distribution, Zeta potential, and encapsulation efficiency. The results showed that the particle sizes were all around 100 nm; PDI was less than 0.2; Zeta potential was around 0 mV; and encapsulation efficiency was 90%, which met the immune requirements.

[0308] 9. Animal Immunization

[0309] The purified mRNA-gE-LNP was adjusted to a concentration of 100 μg / ml with PBS and immunized into Balb / c mice. The immunization procedure was as follows: each group of mice was intramuscularly injected at 0 and 3 weeks, with an immunization dose of 100 μl, and the immunization dose for each mouse was about 5 μg. Blood was collected from the eye sockets at 2 and 5 weeks after immunization to detect the level of humoral immunity; spleen lymphocytes were collected at 5 weeks after the mice were killed to detect the level of cellular immunity.

[0310] 10. Immune assessment

[0311] Humoral Immunity Assessment

[0312] The gE extracellular domain protein was used as the coating protein, with a coating amount of 50 ng / well, and the coating was carried out overnight at 4°C. The 2nd and 5th week sera were graded diluted and then tested by ELISA to evaluate their binding activity. The fitting curves were summarized and analyzed using Graphpad Prism.

[0313] Cellular Immunity Assessment

[0314] After the spleen lymphocytes were separated, the concentration of spleen lymphocytes was adjusted to 1.2 × 10 6 cells / 200μl, incubate overnight in a CO2 incubator at 37℃. After centrifugation, resuspend the cells with 50μl culture medium, add 50μl of 4μg / ml peptide library working solution, 5μg / mL co-stimulatory antibody CD28, 5μg / mL co-stimulatory antibody CD49d, mix and incubate for 1 hour, add 5μg / mL brefeldin A, and incubate for 5h under the same conditions to prevent the release of cytokines. Wash the cells twice with 200μl buffer, add 2.5μg / mL CD16 / 32 antibody, and incubate at 4℃ in the dark for 10min to block the nonspecific binding of short Fc. Wash the cells twice with 200μl buffer, take 100μl Zombie NIR dye (1:500) and resuspend the cells, and keep them in the dark for 20 minutes at room temperature. Wash the cells twice with 200 μl buffer, add 1.25 μg / mL FITC anti-mouse CD4 Antibody and 5 μg / mL PerCP / Cyanine5.5 anti-mouseCD8a Antibody, the solution volume is 100 μl, and incubate at 4°C in the dark for 30 minutes. After fixation and membrane permeabilization, add 1.25 μg / mL APC anti-mouse IL-2 Antibody, 1.25 μg / mL PE anti-mouse IFN-γ antibody, 1.25 μg / mL BrilliantViolet 421 TM Anti-mouse TNF-αAntibody, solution volume 100μl, incubate at room temperature in the dark for 30min. After washing twice, resuspend the cells in 200μl, collect 10W events of live cells for flow cytometry analysis.

[0315] The results are as follows Figure 5 As shown, the results showed that: (1) After 2 immunizations (5W), strong antibody levels were stimulated, and the antibody levels of mRNA-571 and 591 were significantly higher than those of mRNA-623. (2) All mRNA groups of mice significantly induced antigen-specific functional T cell immune responses, including CD4+ and CD8+ T cell immune responses, and were significantly higher than those of the control group. (3) The level of CD4 T cells secreting IFN-γ induced by mRNA-571 mice was significantly higher than that of mRNA-623, and the level of CD8 T cells secreting IFN-γ induced by mRNA-591 mice was significantly higher than that of mRNA-623.

[0316] 11. Comparison between mRNA-gE truncated vaccine and other vaccines

[0317] Balb / c and C57BL / 6 mice were immunized with mRNA-571, mRNA-591, shingrix, and HZV-live, respectively. The immunization procedure was as follows: 5 mice per group, intramuscular injection at 0 and 3 weeks. The immunization dose of mRNA vaccine was 10μg per mouse; the immunization dose of shingrix vaccine and attenuated live vaccine HZV-live per mouse was one-tenth of the vaccine, and the attenuated live vaccine HZV-live was only immunized once at 3 weeks. Five weeks after immunization, the mice were killed and blood was collected to detect the humoral immunity level, and spleen lymphocytes were taken to detect the cellular immunity level.

[0318] The results are as follows Figure 6 As shown, the results showed that: (1) The antibody response trends in the two strains were consistent, and the induced responses of mRNA vaccines 571 and 591 were comparable, which were superior to shingrix and the live attenuated vaccine HZV-live. (2) In both strains of mice, mRNA vaccines 571 and 591 significantly induced antigen-specific functional T cell immune responses (including CD4+ and CD8+ T cell immune responses), and were significantly superior to shingrix and the live attenuated vaccine HZV-live. (3) The CD4 T cell levels of IL-2 induced by mice immunized with mRNA vaccines 571 and 591 were significantly higher than those immunized with shingrix and the live attenuated vaccine HZV-live, which is speculated to induce long-term immunity.

[0319] 12. Comparison between adenovirus gE truncated vaccine and vaccine

[0320] The truncated sequence of gE-573 was selected to prepare adenovirus vaccine. Adenovirus Ad-573, shingrix, and HZV-live were used to immunize C57BL / 6 mice.

[0321] The immunization procedure was as follows: 5 mice per group were injected intramuscularly at 0 and 3 weeks. The immunization dose of adenovirus vaccine was 10^10VP per mouse; the immunization dose of shingrix vaccine and attenuated live vaccine HZV-live per mouse was one-tenth of the vaccine. Five weeks after immunization, the mice were killed and blood was collected to detect the humoral immunity level, and spleen lymphocytes were collected to detect the cellular immunity level.

[0322] The results are as follows Figure 7 As shown, the results showed that mice immunized with Ad-573 and Shingrix induced comparable levels of IFN-γ-secreting CD4 T cells.

[0323] The description of the above embodiments is only used to understand the method and core idea of ​​the present invention. It should be pointed out that for ordinary technicians in this field, several improvements and modifications can be made to the present invention without departing from the principle of the present invention, and these improvements and modifications will also fall within the scope of protection of the claims of the present invention.

Claims

1. A gE protein antigen variant, characterized in that: The gE protein antigen variant includes a truncation of the carboxyl terminal of any one amino acid residue selected from amino acid residues 547 to 623 in the gE antigen, wherein the amino acid residue position refers to the amino acid sequence SEQ ID NO: 1; Preferably, the gE antigen variant comprises a polypeptide with a carboxyl terminal truncation of an amino acid residue selected from positions 547, 551, 556, 561, 566, 571, 576, 581, 586, 591, 596, 601, 606, 611, 616, 621; Preferably, the amino acid sequence of the gE antigen variant is at least 90%, preferably at least 95%, preferably at least 96%, preferably at least 97%, preferably at least 97%, preferably at least 98%, preferably at least 99% identical to the amino acid sequence shown in any one of SEQ ID NOs: 2-18; Preferably, the amino acid sequence of the gE protein antigen variant is shown in any one of SEQ ID NOs: 2-18; Preferably, the amino acid sequence of the gE protein antigen variant is as shown in SEQ ID NO:7 or SEQ ID NO:

11.

2. A nucleic acid molecule, characterized in that The nucleic acid molecule comprises a nucleotide sequence encoding the gE protein antigen variant according to claim 1.

3. A carrier, characterized in that The vector comprises the nucleic acid molecule of claim 2; Preferably, the vector comprises a plasmid vector, a lentiviral vector, an adenoviral vector, an adeno-associated viral vector, a piggyBac vector or a Sleeping Beauty transposition vector.

4. A cell, characterized in that The cell comprises the gE protein antigen variant according to claim 1, the nucleic acid molecule according to claim 2, and the vector according to claim 3; Preferably, the cell comprises a prokaryotic cell or a eukaryotic cell; Preferably, the eukaryotic cells include 293T cells.

5. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the gE protein antigen variant according to claim 1, the nucleic acid molecule according to claim 2, the vector according to claim 3, and the cell according to claim 4.

6. A vaccine, characterized in that The vaccine comprises an active ingredient, wherein the active ingredient comprises an RNA polynucleotide having an open reading frame encoding at least one gE protein antigen variant according to claim 1, and / or the gE protein antigen variant according to claim 1; Preferably, the vaccine comprises an RNA vaccine, a protein vaccine or a viral vector vaccine; Preferably, the RNA vaccine comprises an RNA polynucleotide having an open reading frame encoding at least one gE protein antigen variant according to claim 1; Preferably, the open reading frame of the RNA polynucleotide is codon optimized; Preferably, the RNA polynucleotide comprises at least one chemical modification; Preferably, the chemical modification is selected from any group consisting of pseudouridine, N1-methylpseudouridine, N1-ethylpseudouridine, 2-thiouridine, 4′-thiouridine, 5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine and 2′-O-methyluridine; Preferably, at least 50% of the uracil in the RNA polynucleotide is chemically modified; Preferably, at least 60% of the uracil in the RNA polynucleotide is chemically modified; Preferably, at least 70% of the uracil in the RNA polynucleotide is chemically modified; Preferably, at least 80% of the uracil in the RNA polynucleotide is chemically modified; Preferably, at least 90% of the uracil in the RNA polynucleotide is chemically modified; Preferably, at least 100% of the uracil in the RNA polynucleotide is chemically modified; Preferably, the chemical modification is at position 5 of uracil; Preferably, the RNA polynucleotide further comprises a 3'-UTR and / or at least one 5'-UTR; Preferably, the RNA polynucleotide further comprises a 3'-UTR and at least one 5'-UTR; Preferably, each of the at least one 3'-UTR and the at least one 5'-UTR are heterologous to each other; Preferably, the at least one 3'UTR is derived from a gene selected from the group consisting of: a housekeeping gene, a gene encoding a membrane protein, a gene involved in cellular metabolism, a gene involved in transcription, translation and replication processes, a gene involved in protein modification and a gene involved in cell division; Preferably, the at least one 5'-UTR is derived from a gene selected from the group consisting of: housekeeping genes, genes encoding membrane proteins, genes involved in cellular metabolism, genes involved in transcription, translation and replication processes, genes involved in protein modification and genes involved in cell division; Preferably, the RNA polynucleotide is capped; Preferably, the capping includes cap0, cap1, and cap2; Preferably, the RNA polynucleotide is tailed; Preferably, the tailing comprises tailing by cleavage and polyadenylation specific factors, cleavage stimulating factors, cleavage factor I and cleavage factor II, poly(A) polymerase, poly(A) binding protein, and paired proteins; Preferably, the tailing comprises a poly(A) tail; Preferably, the RNA polynucleotide is capped and tailed; Preferably, the RNA polynucleotide has a 5′ end cap, an open reading frame encoding at least one gE protein antigen variant according to claim 1, and a 3′ polyadenylation tail; Preferably, the 5′ end cap comprises 7mG(5′)ppp(5′)N1mpNp or comprises 7mG(5′)ppp(5′)N1mpNp; Preferably, the poly(A) tail has a length of about 20 to about 300 adenine nucleotides, preferably about 40 to about 200 adenine nucleotides, more preferably about 50 to about 100 adenine nucleotides, even more preferably about 60 to about 70 adenine nucleotides; Preferably, the RNA vaccine is multivalent; Preferably, the RNA vaccine is formulated for delivery on a carrier; Preferably, the carrier includes dendritic cells, cationic nanoemulsions, cationic polypeptides and polymers, liposome polymers, liposome complexes, and lipid nanoparticles; Preferably, the carrier is selected from lipid nanoparticles; Preferably, the lipid nanoparticles include cationic lipids, PEG-modified lipids, sterols and non-cationic lipids; Preferably, the cationic lipid is selected from the group consisting of: 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA) and di((Z)-non-2-en-1-yl)-9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319); Preferably, the protein vaccine comprises the gE protein antigen variant according to claim 1; Preferably, the protein vaccine is carried by a carrier, and the carrier includes serum albumin, immunoglobulin molecules, thyroglobulin, ovalbumin, tetanus toxoid, diphtheria toxoid, genetically modified cross-reactive substances of diphtheria toxoid, CRM197, meningococcal outer membrane protein complex and Haemophilus influenzae protein D, rEPA, keyhole limpet hemocyanin, and / or flagellin; Preferably, the protein vaccine is presented by a variety of antigen presentation systems; Preferably, the antigen presentation system comprises one or more of a Lys-based dendritic structure, a helper T cell epitope, an immunostimulatory lipophilic moiety, a cell penetrating peptide, free radical-induced polymerization, self-assembled nanoparticles, and gold nanoparticles; Preferably, the viral vector vaccine comprises a nucleotide sequence encoding an open reading frame of at least one gE protein antigen variant according to claim 1; Preferably, the vectors in the viral vector vaccine self-assemble into virus-like particles; Preferably, the vector comprises a self-inactivating vector; Preferably, the virus is selected from the group consisting of a lentivirus, an influenza virus, a hepatitis virus, an alphavirus, a filovirus, an adenovirus, an adeno-associated virus and / or a flavivirus; Preferably, the virus is an adenovirus or an adeno-associated virus; Preferably, the virus is an adenovirus; Preferably, the nucleotide sequence is codon-optimized or codon-degenerate; Preferably, the nucleotide sequence has codon usage altered from the natural type; Preferably, the vaccine further comprises gI, gB, gH, gK, gL, gC, gN and / or gM glycoprotein of varicella-zoster virus; Preferably, the vaccine further comprises a pharmaceutically acceptable adjuvant; Preferably, the pharmaceutically acceptable adjuvants include adjuvants required for intravenous drip, subcutaneous injection, intravenous push injection, intravitreal injection, and intramuscular injection.

7. A derivative of a gE protein antigen variant, characterized in that: The derivative comprises a complex formed by directly or indirectly coupling the gE protein antigen variant according to claim 1 to a detectable marker; Preferably, the detectable label comprises a fluorescent dye, a chemiluminescent compound, a radioisotope, an electron-dense reagent, an enzyme, a colored particle, or biotin.

8. Any of the following applications, characterized in that: The applications include: 1) Use of the gE protein antigen variant according to claim 1 in the preparation of a product for detecting varicella-zoster virus; 2) Use of the gE protein antigen variant according to claim 1 in preparing, capturing or screening antibodies that recognize varicella-zoster virus gE protein; 3) Use of the gE protein antigen variant according to claim 1, the nucleic acid molecule according to claim 2, the vector according to claim 3, the cell according to claim 4, the pharmaceutical composition according to claim 5 or the vaccine according to claim 6 in the preparation of a product for treating or preventing varicella zoster virus-related diseases; 4) Use of the gE protein antigen variant according to claim 1, the nucleic acid molecule according to claim 2, the vector according to claim 3, the cell according to claim 4, the pharmaceutical composition according to claim 5 or the vaccine according to claim 6 in the preparation of a product for inhibiting varicella-zoster virus; 5) Use of the gE protein antigen variant according to claim 1, the nucleic acid molecule according to claim 2, the vector according to claim 3, the cell according to claim 4, the pharmaceutical composition according to claim 5 or the vaccine according to claim 6 in the preparation of antibodies against gE protein; 6) Use of the gE protein antigen variant according to claim 1, the nucleic acid molecule according to claim 2, the vector according to claim 3, the cell according to claim 4, and the pharmaceutical composition according to claim 5 in the preparation of a vaccine.

9. Any of the following methods, characterized in that: The method comprises: 1) A method for screening, detecting or isolating antibodies to the varicella-zoster virus gE protein, characterized in that the method comprises using the gE protein antigen variant according to claim 1 to screen, detect or isolate antibodies to the varicella-zoster virus gE protein; 2) A method for producing the gE protein antigen variant according to claim 1, characterized in that the method comprises the following steps: (i) using the vector of claim 3 to transform into a host cell, or directly using the cell of claim 4; (ii) culturing the host cell or cells in step (i) under suitable conditions; (iii) isolating and purifying the gE protein antigen variant according to claim 1 from the host cell culture fluid; 3) A method for preparing antibodies against varicella-zoster virus gE protein, characterized in that the antibodies are obtained by immunizing non-human animals using the gE protein antigen variant according to claim 1, the nucleic acid molecule according to claim 2, and the vector according to claim 3; Preferably, the non-human animal is a vertebrate; Preferably, the vertebrate comprises mice, rats, guinea pigs, rabbits, sheep, non-human primates.

10. A detection / prevention / treatment reagent, a test paper and a kit containing the same, characterized in that: Containing the gE protein antigen variant according to claim 1, the nucleic acid molecule according to claim 2, the vector according to claim 3, the cell according to claim 4, the pharmaceutical composition according to claim 5, the vaccine according to claim 6 or the derivative according to claim 7.

Citation Information

Patent Citations

  • Antibody-metal ion complexes

    US4741900A

  • Stabilised mRNA with an increased g / c content and optimised codon for use in gene therapy

    WO2002098443A2

  • Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof

    CN103827131A

  • Nucleic acid vaccines for varicella zoster virus (VZV)

    CN108472309A

  • Truncated varicella-zoster virus gE protein and application thereof

    CN116655748A